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ABSTRACT OF THE DISSERTATION
Allosteric Modulation of Metabotropic Glutamate Receptor 5 as a Treatment for Pain
by
Michael Christopher Montana
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2012
Professor Robert Gereau, Chairperson

Metabotropic glutamate receptor 5 (mGlu5) has been suggested to play a role in
the development and maintenance of chronic pain. mGlu5 is expressed at synapses
throughout the pain neuraxis where it is believed to modulate the function of ion channels
that underlie nociceptive transduction and transmission. Injections of mGlu5 agonists
cause hypersensitivity or nocifensive behavior when administered peripherally,
intrathecally, and centrally. In addition, pharmacological antagonism of mGlu5 has been
suggested to be analgesic in a variety of animal pain models. Unfortunately, the
selectivity of antagonists used in these studies has been called into question, suggesting
that at least some of the analgesic properties of putatively selective mGlu5 antagonists
may be due to off-target effects. Despite a wealth of data supporting the targeting of
mGlu5 to treat pain, both antagonist selectivity issues and the lack of an mGlu5
antagonist approved for use in humans have hindered testing beyond the preclinical stage.
To address this issue I assessed the pain behavior of mice with a genetic absence of
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mGlu5. mGlu5 KO mice exhibit pain-like behaviors, however the duration and intensity
of these behaviors are attenuated in multiple nociceptive tests, including spontaneous
nociceptive behavior in the formalin test, and mechanical hypersensitivity induced by
Complete Freund’s Adjuvant. In addition, I assessed the analgesic properties of fenobam,
[N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea], an
anxiolytic recently identified as a selective and potent non-competitive negative allosteric
modulator of mGlu5, and previously shown to be safe and effective in clinical trials of
human anxiety. I found Fenobam to be analgesic in models of chemical nociception and
inflammatory pain. Fenobam was also found to be without analgesic effect in mGlu5 KO
mice, suggesting that its analgesic effect is mediated via mGlu5. Further assessment of
both mGlu5 KO mice and the effects of fenobam suggested that mGlu5 may play a role
in locomotion, weight gain, and appetite. Fenobam increases locomotive behavior,
suggesting that antagonists of mGlu5 may exert analgesic effects without causing doselimiting sedation. Overall these data suggest that mGlu5 is an important modulator of
nociceptive plasticity, and that allosteric modulation of mGlu5 may represent a
pharmacologic target for the treatment of pain.
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Chapter 1
Introduction to the Role of Metabotropic
Glutamate Receptor 5 (mGlu5) in Pain

1

The study of pain has occupied philosophers, physicians, and scientists
throughout recorded history. Pain is a multifaceted sensory and emotional experience that
is commonly associated with bodily harm or injury. The English word “pain” has roots in
the Latin word poena or “punishment.” When considering physiological pain,
punishment seems appropriate; physiological pain acts as a defense system that allows
individuals to avoid or withdraw from noxious and dangerous stimuli. Following tissue
damage, tenderness and hypersensitivity at and around the site of injury encourage
healing, by punishing an organism for overusing the affected area. Importantly, while
physiological pain may be prolonged, it is reversible, and as healing occurs the necessity
for pain to serve a protective role diminishes and the pain regresses. However, pain can
outlast the injury and become chronic or pathologic.
The existence of chronic pain is a major clinical problem confronting patients and
their physicians (National Center for Health Statistics, 2007). This document will focus
on the role that metabotropic glutamate receptor 5 (mGlu5) plays in the development and
maintenance of chronic pain and the possible clinical utility that mGlu5 antagonists may
have in alleviating that pain. In addition I will discuss the role that mGlu5 plays in
physiological non-pain mechanisms to provide a context in which to address potential
side effects of mGlu5 antagonists.
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Pain Terminology and Definitions
Catalogued debate regarding the nature of pain dates to at least ancient Greece
where Aristotle viewed pain as an emotion (Perl, 2007). An emotional aspect of pain
remains in modern times, and the International Association for the Study of Pain (IASP)
defines pain as “an unpleasant sensory and emotional experience associated with actual
or potential tissue damage or described in terms of such damage” (Loeser and Treede,
2008). While current views of pain are shaped by a detailed understanding of anatomy
and neurophysiology, many questions remain. Discoveries over the last several hundred
years have shown that specific neuro-anatomical pathways are involved in the
transmission of acute painful stimuli from the periphery to higher brain centers, and that
these transmissions cross multiple synapses within both the spinal cord and the brain
(Milan, 1999). We also know that pain perception can vary greatly depending on
environment or context. For example, injury may result in previously non-painful stimuli
being perceived as painful. However, the specific mechanisms that underlie these changes
are not completely understood. Plasticity at multiple ascending synapses throughout the
pain neuraxis likely plays a role in some of the profound changes that can occur in pain
perception. In addition modulation of ascending afferents by descending neurons (e.g.
pontospinal) within the spinal cord can also affect the perception of painful stimuli
(Howorth et al., 2009). Individuals that suffer massive traumatic injuries may report no
pain at the time of the injury (Melzack and Wall, 1982). Unfortunately the reverse is also
true, and both individuals with only minor injuries (Melzack and Wall, 2003, p. 276), and
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those who have no discernible injury (Wolfe et al, 1990, 2010) may report debilitating
pain. A classic example is phantom pain, where painful sensations are perceived in a
missing limb following amputation. The fact that pain can still be perceived in the
missing limb is viewed as evidence that peripheral input is not required to experience
pain. In addition, as the peripheral input is absent, changes elsewhere in the nervous
system, either in the spinal cord or higher brain regions, must underlie this increased pain
perception.
Phantom limb pain is but one example of how plasticity within the nervous
system may contribute to sensitization following injury and the development of chronic
pain. Nociception is the “neural process of encoding and processing noxious
stimuli” (Loeser and Treede, 2008), and the perception of pain relies on the activation of
neurons within the peripheral somatosensory system as well as the awareness of that
stimulation due to activation of neurons in the spinal cord and brain. Altered pain
perception following injury is thought to be due to increased responsiveness and reduced
thresholds of neurons in the peripheral and central nervous system. Injuries that result in
tissue damage often induce an inflammatory reaction that contributes to the sensitization
of peripheral somatosensory neurons, reducing their firing threshold and increasing their
responsiveness to stimuli within their receptive fields. This phenomenon is termed
peripheral sensitization (Loeser and Treede, 2008). In addition, neurons within the central
nervous system may become sensitized and exhibit increased responsiveness to input
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from peripheral afferents, a phenomenon known as central sensitization (Loeser and
Treede, 2008).
Peripheral and central sensitization occur in nociceptive neurons, which are
somatosensory neurons that encode potentially or actually tissue damaging events, known
as noxious stimuli (Loeser and Treede, 2008). Peripheral nociceptive neurons have nerve
endings in the periphery that transduce and encode noxious stimuli. The perception of
pain can arise from direct external stimulation and activation of nociceptors (nociceptive
pain) or from damage or disease within the somatosensory system itself (neuropathic
pain). It is important to note from the IASP definition of pain above the emotional
component  pain is more than just sensation of noxious stimuli, it also has a strikingly
negative affective component that can radically alter behavior and quality of life.
Unpleasantness, distress, discomfort, and suffering can all be emotional descriptions of
pain perception, and an integrated view of pain includes both an emotional and a sensory
component. Thus factors that affect both the sensation of pain, such as the enhancement
or blockade of peripheral nociceptive neural activity, and the emotional and behavioral
responses, such as anxiety, stress, and awareness, may play important roles in pain
perception. While acute pain is generally viewed as physiological and protective,
prolonged pain that outlasts the inciting stimulus can be detrimental and may be viewed
as pathological. Pathophysiological changes within the nervous system can allow pain to
be perceived in the absence of ongoing nociception. In addition, the perception of pain
can be brought on by a multitude of different inciting stimuli. Pain is a hallmark of many

5

disease processes and can by classified in multiple ways (Loeser and Treede, 2008; Woolf
et al., 1998), including by location (e.g. abdominal pain), by mechanism (e.g. neuropathic
pain), as a component of a disease (e.g. arthritis pain), by inciting factor (e.g. postoperative pain), and by responsiveness to medication (e.g. indomethacin responsive
headache), just to name a few.
The significant impact pain has on both individuals and society has made it a
focus of major research efforts. Much of this research has been conducted in human
subjects. However, the ethical and practical limitations of conducting pain research only
in humans have resulted in the development of many laboratory animal models for the
study of pain. The complex nature of observing and interpreting animal behavior warrants
a closer look at some of these models.
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The Applicability of Pain Assessment in Rodents to Humans
Much of the evidence and data presented below about the analgesic efficacy of
mGlu5 antagonists are derived from behavioral animal models of pain. It is important to
discuss some of the limitations of these animal models and how they are thought to apply
to human pain conditions. As discussed above, human pain is a subjective experience that
can be influenced by a multitude of factors, including level of awareness, surrounding
environment, and stress. Animals possess many neuroanatomical pathways for
transmitting information regarding peripheral nociception similar to those found in
humans (Willis and Westlund, 1997). Additionally, as is true for humans, reported
measurements of nociception in mice are susceptible to environmental and experimental
state influences such as genetic background (Mogil et al., 1999), housing conditions,
experimenter presence, diet, age, gender, (Mogil, 2009) and social cues (Langford, 2006).
However, as elegantly stated by Bud Craig “A rat is not a monkey is not a
human.” (Craig, 2009), and differences between humans and experimental laboratory
animals exist with regard to both neuroanatomy, and, importantly, the ability to report
painful stimuli. Animals simply cannot verbalize when they are in pain, and surrogate
measurements must be used such as withdrawal from stimuli, escape from noxious
locations (e.g. extreme heat or cold), licking, shaking, or lifting of injured areas, as well
as more complex behavioral readouts such as conditioned place preference (King et al.,
2009). Technically we can never know whether an animal is in pain and thus
hypersensitivity and hyperalgesia (which may include decreased threshold to stimuli and
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increased responses to suprathreshold responses), and spontaneous behavior are used as
surrogates to infer pain. Of course it should be noted that no purely objective parameters
such as specific biomarkers currently exist for pain in humans either, and while human
possess the benefit of language for communicating, pain is still a subjective experience in
our species as well.
While the inability to determine what experimental animals are subjectively
experiencing marks a significant challenge to the direct applicability of animal models to
human pain conditions, there are a number of factors that contribute to the utility of
animal models of experimental pain, both now and in the foreseeable future. One of the
foremost is the ability to use knockout animals to assess the role that specific
monogenetic influences play in pain behaviors. Knockout mice have been generated for a
number of proteins involved in pain transduction and perception and have greatly
contributed to our understanding of the specific roles these proteins play in pain
transmission. For example, mice lacking the heat-gated cation channel TRPV1 show
deficits in development of heat hypersensitivity following inflammation (Caterina et al.,
2000) and mice lacking mu-opioid receptors have profound impairments in their
responses to the opioid agonist morphine (Matthes et al, 1996). While important
considerations regarding compensation and genetic background exist when assessing
genetically modified animals (Larviere et al., 2001), genetically modified mice have
proven indispensable in assaying the necessity for a specific protein in pain perception, or
the target of action of an analgesic drug. In addition, the testing of animals is beneficial
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for economic and ethical reasons : the effects of single genes or pharmacological
treatments can be assessed in a battery of pain-related behavioral tests that would be costprohibitive (due to sheer numbers) or unethical (e.g. controlled neuropathic pain injury
models) to perform in humans.
Specific pain related behavioral tests described in this thesis include the formalin
test of spontaneous nocifensive behavior, complete Freund’s Adjuvant-induced
mechanical and thermal hypersensitivity, and two models of neuropathic pain: the chronic
constriction injury model, and the spared nerve ligation model. These models are
discussed below.

Spontaneous Formalin-Induced Nocifensive Behavior: The formalin test is a model of
acute to moderate duration pain. Spontaneous nocifensive behaviors (including licking,
lifting, guarding, and flinching) are induced by the injection of a dilute solution of
formalin into the plantar surface of the mouse’s hindpaw (Dubuisson ad Dennis, 1977).
Formalin concentrations used are generally between 1% and 5% (of a 37% w/w solution
of formaldehyde), dissolved in normal saline. Injection volumes for mice are usually
limited to 10 microliters, due to volume constraints of the hindpaw. Immediately post
injection a characteristic biphasic response is seen, the first phase of which lasts for
approximately 5 to 10 minutes, followed by a period of inactivity, and then a second
phase of nociceptive behavior beginning around 15 to 20 minutes and lasting
approximately another 15 to 20 minutes. Spontaneous nocifensive behaviors cease at
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from between 45 to 60 minutes, however hypersensitivity to mechanical and thermal
stimuli may remain for days to weeks (Kolber et al, 2010; Wu et al., 2004). Spontaneous
nocifensive behaviors can be scored by an observer and the responses of mice in different
treatment groups or of different genotypes can be compared.
The first phase of the formalin test is believed to be due to the direct activation of
the ion channel TRPA1 (Macpherson et al., 2007; McNamara et al., 2007), although
concentrations of formalin that are used for behavioral testing most likely also cause
generalized inflammation and no specific tissue damage. Initially it was felt that the
second phase was solely due to ongoing inflammation and central sensitization within the
spinal cord (McMahon and Koltzenburg, 2005, p.183), however continued discharge of
A-delta and C-fibers that begin firing 15 minutes post injection suggest that at least some
of the second phase responses are due to ongoing peripheral nociceptor activity (Puig and
Sorkin, 1996). Analgesics that are known to modulate human pain, including opioids,
NSAIDs, and the anti-convulsant gabapentin (Le Bars et al., 2001; Munro et al., 2007)
are known to reduce spontaneous formalin behavior. The formalin test is felt to be one of
the most predictive models of acute animal pain, in that drugs that are effective analgesics
in humans are also largely effective in reducing acute pain in animals (Le Bars et al.,
2001).

CFA-Induced Mechanical and Thermal Hypersensitivity: Complete Freund’s Adjuvant
(CFA) is an emulsion of heat-killed Mycobacterium in paraffin oil. CFA causes an
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inflammatory response when injected into tissues due to its ability to attract macrophages
and other immune cells. This results in hypersensitivity to both mechanical and thermal
stimuli in animals (Alter et al., 2010; Ren, 1999) and in man (Gould, 2000). Thresholds
to mechanical and thermal stimuli can be monitored in resting animals. Baseline
measurements are made and then hypersensitivity is induced by subcutaneous injection of
10 microliters of CFA into the dorsal hindpaw. The effects of both drugs and genotype on
the development of and recovery from hypersensitivity can be assessed. Mechanical
hypersensitivity is commonly assessed on the hindpaw, but can also be assessed on the
face or knee joint. Calibrated nylon monofilaments of increasing tensile strengths are
applied to the plantar surface of the foot, and the bending force of the filament from
which the mouse withdraws is recorded. Sensitivity to heat stimuli is measured in a
similar manner, except the mouse is placed on a glass platform and a focused radiant light
source is used to deliver a thermal stimuli to the hindpaw. The latency to withdraw from
the heat source is used as the behavioral read out (Hargreaves et al., 1988).

Neuropathic Pain Models: The development of neuropathic pain results from direct
damage or lesion to the somatosensory nervous system (Loeser and Treede, 2008).
Multiple models of neuropathic pain exist derive from different injuries to the nervous
system. The most popular models try to mimic the partial nerve injury that is usually seen
in neuropathic pain patients by inducing only a partial injury instead of a complete lesion
that would only be seen following overwhelmingly severe injuries, such as amputation.
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Two of the most common forms of inducing neuropathic pain are to perform a loose
ligation around the sciatic nerve using chronic gut suture (Bennett and Xie, 1988) and to
selectively lesion two of the three primary distal branches of the sciatic nerve while
leaving the third intact (Decosterd and Woolf, 2000). These models are respectively
termed the chronic constriction injury model (CCI) and the spared nerve injury (SNI)
model. Both models induce hypersensitivity to thermal and mechanical stimuli that is
responsive to known analgesics. The SNI model involves the transection of the tibial and
common peroneal branches of the sciatic nerve, while leaving the sural nerve intact. This
results in hypersensitivity developing on the lateral side of the hindpaw in the territory of
the sural nerve, which can be specifically probed for hypersensitivity. The SNI surgery
itself is viewed as relatively easy to perform, however testing post injury requires careful
attention to the area of the paw being probed as significant differences are found in
responsiveness to stimuli applied to different nerve territories (e.g. sural vs. saphenous;
Decosterd and Woolf, 2000; Zhao et al., 2004). The CCI model produces swelling and
inflammation around the nerve and is intended to damage some but not all of the sciatic
axons. It is inherently difficult to reproduce consistently and can result in variable
responses to stimuli. However, testing of hypersensitivity is quite simple, because the
entire paw of the organism is theoretically hypersensitized. Additional models of
neuropathic pain also try to replicate diabetic peripheral neuropathy,drug-induced
neuropathic pain, and direct spinal cord injury (Sandkuhler, 2009).
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These animal models and others used throughout the pain research field represent
powerful tools, especially in the assessment of new pharmacological treatments for
painful conditions, while simultaneously allowing for the assessment of potential
undesirable effects that might endanger human patients and volunteers. It is also
important to note that genetic and pharmacological manipulations of behaving animals
may alter the behavioral readouts used to assess the analgesic effect of a given situation.
For example, a drug that induces somnolence or causes motor impairment may also alter
a behavioral readout surrogate of analgesia that requires intact motor function,
independent of its analgesic effect (e.g. paw withdrawal). For this reason in addition to
the pain related behavioral tasks presented below I have also assessed locomotion, motor
coordination, and other potential effects, which if altered, could confound interpretations
of pain-related behavior. Ultimately animal testing is an important and useful component
of pain research, so long as the obvious caveats are addressed. Many analgesics currently
used in humans have been shown to be efficacious in animal models of pain (Mogil,
2009), and molecules and techniques tested in animals have been successfully applied to
the treatment of human pain conditions. Still no panacea for chronic pain exists. While
current treatment regimens are very effective in treating some types of pain (e.g. acute
post-operative pain), the effective treatment of chronic pain is a largely unmet goal. Also
as discussed below, many highly effective analgesics suffer from poor therapeutic index.
The need for additional treatments is paramount and the use of animal pain models will
be critical to future endeavors.
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Examples of Currently Available Pharmacological Therapeutics and Their Limitations
Current treatments for pain rely on a variety of pharmacological therapeutics,
surgical interventions, physical therapy, psychological/psychiatric approaches, and their
use in combination. Present pharmacological therapies include several different classes of
medication such as anti-pyretic agents, nerve-blockers, opioids, and anti-epileptics. While
many of these agents are highly effective in controlling pain, they all have specific
settings in which they are and are not useful, as well as dose-limiting side effects.
Additional drugs in the pharmacological armamentarium may address some of the
limitations of currently available therapeutics and bridge current gaps in coverage.
Pain relievers derived from natural products have long been used by human
civilizations. Two of the most prominent examples are willow bark preparations that
contain salicylic acid (from which the antipyretic analgesic aspirin can be synthesized)
and the poppy seed extract opium (which contains the opioid narcotic morphine). Despite
centuries of use, the precise mechanisms of action through which these drugs exert their
analgesic effects have only come to light in the last half century (Vane, 1971; Pert, 1973).
While both salicylate derivatives and opiates are outstanding analgesics, they are not
effective in the treatment of all types of pain and have undesirable side effect profiles that
can result in significant morbidity when used long term. The discovery of both new
analgesics and the analgesic properties of drugs originally developed for different
purposes has generated major advances in the ability to treat chronic pain. Here I will
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discuss the clinical utility and dose limiting effects of a few classes of analgesic
medications.

Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Antipyretics: Arachidonic acid
(AA) is synthesized from cell membrane phospholipids in response to a variety of
stimuli, including inflammation (Rao and Knaus, 2008). The enzyme cyclooxygenase
(COX) catalyzes the conversion of AA to prostaglandin G2 (PGG2) and subsequent
intracellular reactions result in the production of several additional prostaglandins
including the pyretic prostaglandin PGE2. Several prostaglandins are pro-algesic and can
sensitize primary afferent nociceptive neurons (Melzack and Wall, 2003, p. 345; Lopshire
and Nicol, 1997) and act synergistically with other inflammatory mediators such as
bradykinin (Taiwo and Levine, 1988). The analgesic effects of NSAIDs, including
salicylate derivatives such as aspirin, are largely attributed to their ability to act as COX
inhibitors and thus decrease the synthesis of prostaglandins (Vane, 1971). NSAIDs have
clinical utility in the treatment of pain, especially in conditions associated with
inflammation, such as rheumatoid arthritis. However, in rheumatoid arthritis, NSAIDs
only provide symptomatic relief and do not alter disease progression (Melzack and Wall,
2003, p. 45). NSAIDs are also useful in the treatment of migraine headache, postoperative pain, and cancer pain (Melzack and Wall, 2003, p. 347). Unfortunately,
nonselective COX inhibitors such as aspirin can be toxic to the GI tract and kidney.
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Aniline derivatives, such as acetaminophen, are antipyretic and analgesic nonNSAIDs, and have fewer side effects than salicylates when dosing guidelines are
maintained (Melzack and Wall, 2003, p. 348). Unfortunately acetaminophen overdose is
also the most common cause of acute liver failure (Ostapowicz et al., 2002), which can
result in fatality or require liver transplant. In addition, acetaminophen lacks peripheral
anti-inflammatory effects, and there are some inflammatory pain conditions, such as
rheumatoid arthritis, in which patients prefer NSAIDs over acetaminophen based on
effectiveness (Wolfe et al., 2000). Thus NSAIDs and antipyretics represent the classical
issues of balancing clinical effectiveness, disease appropriateness, and safety common in
other classes of medication.

Opioids: Opioids inhibit the perception of pain by activating endogenous analgesic
systems in the spinal cord and brain, which in turn modulate ascending pain transmission
along the pain neuraxis (Fields, 2004). Multiple opioid receptor subtypes exist within the
nervous system, however, the primary analgesic actions of most opioids in clinical use
result from activation of the µ-opioid receptor, which is expressed both pre- and postsynaptically throughout the endogenous pain-modulating circuit. Morphine is the
prototypical µ-opioid receptor agonist, and a powerful analgesic (Melzack and Wall,
2003, p. 379). However, concomitant side effects, including nausea, vomiting, narcosis,
constipation, respiratory depression, opiate-induced itch, and tolerance (Melzack and
Wall, 2003, p. 389-392) require a careful assessment of the risk / benefit ratio when
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administering opioids. Additionally, patient perception that addiction is likely (Melzack
and Wall, 2003, p. 385-86) may decrease patient enthusiasm for initiating opioid therapy.
Regardless of these issues, opioids are a mainstay of cancer and peri-operative pain
management. The combination of opioids with adjuvant analgesics (e.g. NSAIDs and
anticonvulsants) can also be used to decrease the dose of opioid required to achieve
analgesia, and thus decrease the incidence of side-effects. The discovery of new drugs
that could act as a opioid adjuvants would be beneficial to the treatment of pain.

Anticonvulsants: Anticonvulsants developed to decrease neuronal firing rates in epilepsy
have been found to possess clinical utility in the treatment of neuropathic pain, possibly
through the modulation of ion channels required for action potential generation (TremontLukats et al., 2000). Gabapentin is a prime example of the successful use of
anticonvulsants as analgesics. Originally developed as an oral anticonvulsant (Bruni et
al., 1991; UK Gabapentin Study Group, 1990; US Gabapentin Study Group No. 5, 1993)
it has been shown to be effective compared to placebo in the treatment of post-herpetic
neuralgia (Rowbotham et al., 1998) and was approved by the FDA for the management of
that condition. The precise mechanism of action by which gabapentin exerts its analgesic
actions is unknown, however it has been suggested that it mediates some of its analgesic
effects via binding to α-2-δ calcium channels (Gee et al., 1998) and inhibiting
neurotransmitter release and ectopic discharge (Pan et al., 1999; Taylor et al., 1998).
Gabapentin has also been shown to be analgesic in multiple animal pain models (refs).
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While generally well tolerated gabapentin administration is not without adverse events,
and gabapentin may cause dizziness and somnolence, as well as rare incidents of lifethreatening angioedema and suicidal ideation (Pfizer, 2010). Still the use of gabapentin as
an analgesic represents a prominent success story in the use of drugs originally developed
for other purposes as analgesics.

Future Directions in Analgesia Development: Rational design of entirely new classes of
analgesics has been based on recent discoveries in signal transduction of nociceptive
stimuli. For example, the algogenic chili pepper extract capsaicin was discovered to
induce pain by selectively activating the heat-sensitive cation channel TRPV1 on
peripheral nociceptors (Caterina et al., 1997). Unfortunately, some setbacks have
occurred, as TRPV1 antagonists have also been shown to induce significant hyperthermia
(Gavva et al., 2008). TRPV1 expression in central brain regions, including the
hippocampus, and the reported role for TRPV1 in mediating long term depression (LTD)
(Gibson et al., 2008), may also represent hurdles to the development of antagonists as
analgesics. It is critical to develop new classes of analgesics based on an understanding of
their roles in pain processing and plasticity. Glutamate receptor signaling is a prime target
for this type of drug development, as its roles in pain processing and plasticity have been
extensively characterized during the last decade.
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Metabotropic Glutamate Receptor 5 (mGlu5) as a mediator of Peripheral and Central
Sensitization and a Potential Therapeutic Target for the Treatment of Pain

Metabotropic Glutamate Receptor Classes and Signaling Cascades: Glutamate is the
primary excitatory neurotransmitter in the vertebrate nervous system. It mediates its
effects via activation of two main classes of receptors: ligand-gated ion channels known
as ionotropic receptors and G-protein coupled metabotropic receptors. Metabotropic
glutamate receptors (mGluRs) belong to the Class C family of G-protein coupled
receptors (GPCRs) whose structure includes a large venus-flytrap-shaped extracellular Nterminal domain where endogenous ligands, synthetic orthosteric agonists, and
competitive antagonists bind. Like all GPCRs, mGluRs possess a seven transmembrane
domain region that is responsible for coupling to G-proteins (Bhave et al., 2003). Within
the mGluR family eight distinct receptor subtypes have been identified. These receptors
are divided into three major groups based on sequence homology, signal transduction
mechanisms, and pharmacological profiles (Conn, 2003). In heterologous systems group
I mGluRs (mGlu1 and 5) couple to the stimulatory G-protein Gq and subsequently to the
activation of phospholipase C (PLC) and the release of intracellular calcium. Group II
(mGlu2 and 3) and III (mGlu4, 6, 7, and 8) mGluRs couple to the inhibitory G-protein
Gi/o and subsequently inhibit adeylyl cyclase. Group II and III mGluRs also couple to the
activation of G-protein coupled inwardly rectifying potassium channels (Knoflach and
Kemp, 1998; Watanabe and Nakanishi, 2003) and the inhibition of voltage gated calcium
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channels (Conn and Pin, 1997). mGluRs are expressed both pre- and post-synaptically:
however group I mGluRs are primarily localized to the postsynaptic density where their
activation results in an increase in neuronal excitability, while group II and III mGluRs
are primarily localized to presynaptic terminals and function as auto-receptors to regulate
neurotransmitter release (Testa et al., 1998; Lovinger and McCool, 1995).

Distribution of mGluRs Throughout the Nervous System: Following the initial discovery
of mGluRs in 1991 and the subsequent discovery of a total of eight members of the
mGluR family, (Masu et al., 1991), mGluRs have been shown to be expressed throughout
the nervous system. Importantly mGluRs are expressed at all levels of the pain neuraxis,
including the spinal cord and periphery (Varney and Gereau, 2002). mGluRs are
expressed extensively throughout the brain, with the notable exception of mGlu6, which
is expressed exclusively in the retina. (Ferraguti and Shigemoto, 2006) mGlu1 exhibits
robust expression in the cerebellar cortex, substantia nigra, and hippocampus as well as
slightly lower expression in neocortex, amygdala, and striatum (Martin et al., 1992).
mGlu5 is found throughout the cerebral cortex, hippocampus, striatum, and amygdala. Of
specific interest to pain processing is the expression of mGlu3, 5, and 7 (Varney and
Gereau, 2002) within the periaqueductal grey (PAG). Ascending fibers carrying pain and
temperature information from the spinal cord via the spinomesencephalic tract synapse
within the PAG. In addition, the PAG plays a major role in the descending modulation of
pain. Another brain region of particular relevance to pain processing is the amygdala.
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Pain is associated with negative emotional responses and in humans the amygdala is an
important center for the processing of emotional information. The amygdala is activated
during pain in both humans and rodents (Schneider et al., 2001; Ji and Neugebauer, 2008;
Kolber, et al., 2010) and activation of group I, II, and III mGluRs within the amygdala (Li
and Neugebauer, 2004 & 2006; Kolber et al., 2010) can modulate nociceptive processing.
Finally, members of all groups are found in the thalamus, with notable expression of
mGlu1, 4, and 7 in nuclei that receive sensory and pain inputs (VPM and/or VPL)
(Lorenco Neto et al., 2000).
Expression of all Group I and II mGluRs as well as mGlu4 and 7 has been noted in
the spinal cord (Karim et al., 2001; Jia et al. 1999; Chiechio et al., 2002; Varney and
Gereau, 2002). Expression levels for mGlu2, 3, and 5 are particularly high in the spinal
cord dorsal horn, where first order peripheral sensory neurons carrying nociceptive
information synapse onto second order neurons, including ascending projection neurons.
In addition, members of all mGluR groups are expressed in the peripheral nervous system
within the cell bodies of the dorsal root ganglia in rats (Carlton and Hargett, 2007), and
mGlu5 has been identified by immunohistochemistry in human DRGs (Valerio et al.,
1997). Over the past two decades a growing body of evidence has contributed to the
hypothesis that metabotropic glutamate receptors, and particular mGlu5, are involved in
both the induction and maintenance of pain.
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The Role of mGlu5 in Pain Plasticity: The first suggestion that mGluRs may play a role
in nociceptive transmission came in 1994 from two separate groups. Young et al. (1994)
demonstrated that the putatively competitive mGluR antagonist L-AP3 inhibited the
excitation of spinal cord dorsal horn neurons induced by the cutaneous application of
mustard oil. This work was extended to suggest that the sustained nociception evoked by
repeated cutaneous application of mustard oil could also be inhibited by blocking the
activation of mGluR mediated intracellular signaling pathways such as PLC (Young et
al., 1995). At the same time, Neugebauer et al. demonstrated that L-AP3 reduced the
responses of hyperexcitable spinal cord neurons following acute inflammation in the knee
joint (Neugebauer et al., 1994). Interestingly, L-AP3 had no effect on either noxious or
innocuous pressures applied to the normal knee joint, suggesting that activation of group
I mGluRs was selective for inflammation-evoked hypersensitivity and not necessary for
the responses elicited under normal conditions. Unfortunately, the non-selective nature of
L-AP3 and other early pharmacological tools used to assess the mGluRs (Schoepp et al.,
1999) make the interpretation of some of these early experiments difficult. However
additional studies using more selective pharmacological agents suggest that activation of
group I mGluRs in both the periphery and the spinal cord is indeed pronociceptive
(Neugebauer et al., 1999; Dolan and Nolan, 2000; Bhave et al., 2001; Karim et al., 2001).
A principal mechanism by which mGlu5 promotes hypersensitivity is through the
modulation of nociceptive transduction channels in peripheral terminals of primary
afferent neurons. For example, peripheral injection of the group I mGluR agonist
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R,S-3,5-dihydroxyphenylglycine (DHPG) results in thermal hypersensitivity in mice
(Bhave et al., 2001; Hu et al, 2002). This is believed to result from the activation of a
complicated signaling pathway where group I mGluR activation couples to PLC
activation, and results in the generation of diacylglcerol, which is metabolized into the
inflammatory mediator arachidonic acid. Further metabolism of arachidonic acid results
in the production of prostaglandins via the cyclooxygenase (COX) pathway and the
eventual sensitization of the capsaicin receptor TRPV1 (Hu et al., 2002), which is
required for the molecular changes underlying inflammation-evoked thermal
hypersensitivity (Caterina et al., 2000; Davis et al., 2000). In sensory neurons, DHPGinduced enhancement of calcium responses following application of the TRPV1 agonist
capsaicin has been primarily attributed to mGlu5 (Hu et al., 2002). mGlu5-mediated
potentiation of these capsaicin-evoked responses is attenuated by both the PLC inhibitor
U73122 and the DAG-lipase inhibitor RHC-8026719, suggesting a prominent role for
mGlu5- stimulated, PLC-activated PIP2 signaling pathways in thermal hyperalgesia.
Additionally, the potentiation of these capsaicin-evoked responses is also blocked by the
COX inhibitors indomethacin and ibuprofen, and the prostanoid receptor antagonist
SC-51089. Results from in vivo studies demonstrate that inhibitors of mGlu5 (MPEP) and
COX (indomethacin, aspirin) block DHPG-induced thermal hyperalgesia (Hu et al.,
2002). Taken together, these data suggest that mGlu5-stimulated PLC activation in
sensory neurons – and the subsequent activation of downstream prostaglandin
inflammatory mediators – promotes thermal hyperalgesia via modulation of TRPV1.
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A prominent role for mGlu5 in the development of central sensitization has also
been suggested. Modulation of ion channels within the spinal cord may contribute some
of the molecular changes that underlie central sensitization (Ji et al., 2003). For example,
decreased potassium channel function or effectiveness could manifest in increased
neuronal excitability. A specific ion channel that is expressed in dorsal horn neurons and
is known to modulate neuronal excitability is KV4.2, which contributes to the fast
transient outward potassium current (IA) (Hu et al., 2003). Genetic deletion of KV4.2
results in increased excitability of dorsal horn neurons and increased sensitivity at
baseline to mechanical stimuli. Interestingly however, KV4.2 knockout mice do not
demonstrate increased hypersensitivity following activation of extracellular signalregulated kinase (ERK) (Hu et al., 2006), a known modulator of pain hypersensitivity (Ji
et al., 1999). ERK is an integrator of intracellular signaling cascades that are initiated in
the spinal cord following painful stimuli, and ERK activation contributes to central
sensitization (Ji et al., 2009). The activation of mGlu5 in the dorsal horn of the spinal
cord functionally couples to the activation of the ERK (Karim et al., 2001) and the
subsequent phosphorylation of Kv4.2 (Hu et al., 2007), which results in increased
excitability of dorsal horn neurons. This mGluR5-ERK-Kv4.2 regulation of dorsal horn
neuronal excitability is believed to represent a cellular underpinning of inflammationinduced central sensitization in the spinal cord. Thus, both peripheral and central
activation of mGlu5 has been demonstrated to modulate pain plasticity.
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Allosteric Modulation of mGlu5
Exciting advances in recent years have yielded numerous small molecule
allosteric modulators of mGluRs that bind within the transmembrane domain at a
topographically distinct location from the glutamate binding site. Pharmacological
dissection that provides much of the evidence of the role mGlu5 plays in pain plasticity
has been largely conducted using these drugs. Allosteric modulators mediate their effects
by exhibiting one or more of three pharmacological properties. First, allosteric
modulators can exhibit affinity modulation and alter the affinity of the receptor for its
endogenous ligand. Second, efficacy modulation may occur such that the binding of an
allosteric modulator alters the strength of the downstream signaling cascades induced by
the orthosteric ligand. Finally some allosteric modulators may have positive or negative
intrinsic activity on the receptor itself such that they function as agonists or inverse
agonists regardless of the binding of the orthosteric ligand. With respect to mGlu5,
positive allosteric modulators (PAMs) increase, and negative allosteric modulators
(NAMs) decrease, the response of the receptor to glutamate. (Conn et al., 2009)
The ligand binding site often has high sequence homology across members of a
family of GPCRs, making development of selective agonists or antagonists against a
specific receptor subtype difficult. However, modern high-throughput screening for
receptor activity modifiers allows for the identification of compounds that bind elsewhere
in the receptor, and has allowed for the development of allosteric modulators that have
improved receptor subtype specificity when compared to compounds that bind at the
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endogenous ligand binding site (Conn et al., 2009). Additionally, some allosteric
modulators do not possess intrinsic activity at the receptor, and only exert an effect when
an orthosteric ligand is bound. These molecules would theoretically exhibit activitydependence, only modulating the system when and where it is activated under
physiological conditions. For these reasons, allosteric modulators represent attractive
candidates for development as pharmacological agents that target mGluRs.
The development of the non-competitive mGlu5 antagonist MPEP (Gasparini et al.,
1999) addressed a need for a selective pharmacological tool to probe the role of mGlu5 in
chronic pain. While the related compound MTEP (Cosford et al., 2003) is generally
thought to be more potent and selective (Lea and Faden, 2006) much of the mGlu5
research over the past decade has utilized MPEP. Systemic MPEP administration reverses
mechanical hyperalgesia induced by the inflammatory agents Complete Freund’s
Adjuvant (CFA) and carrageenan, and oral administration was found to have improved
gastrointestinal safety over the NSAIDs indomethacin and diclofenac (Walker et al.,
2001a). In addition peripherally administered MPEP was found to significantly reduce
CFA induced inflammatory hyperalgesia (Walker et al., 2001b) suggesting a role for
peripherally expressed mGlu5 in pain. Bhave et al. (2001) further expanded upon this
work by demonstrating the expression of group I mGluRs on the peripheral terminals of
nociceptors, and showing that peripheral injection of the group I mGluR agonist DHPG
induces thermal hypersensitivity in mice. This DHPG induced hypersensitivity was
blocked by peripheral injections of MPEP. Furthermore, peripheral injections of MPEP
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were able to prevent and reduce spontaneous behavior following intraplantar formalin
injection (Bhave et al., 2001).
Neuropathic pain has also been suggested to be susceptible to modulation by
mGlu5 antagonists. Intrathecal injection of the mGlu5 antagonist SIB-1757 is able to
reduce mechanical allodynia following spinal nerve ligation (SNL) as well as reverse
SNL-induced thermal hyperalgesia (Dogrul et al., 2000). In addition,
intracerebroventricular (i.c.v.) injections of MPEP dose-dependently inhibit cold
hypersensitivity following chronic constriction injury (CCI) of the sciatic nerve in rats
(Urban et al., 2003). Brain receptor occupancy studies following systemic MPEP
injections suggested that >90% receptor occupancy is required for effective analgesia. Of
note, neither intrathecal nor intraplantar injections of MPEP were found to be effective in
reducing cold hypersensitivity post-CCI (Urban et al, 2003), however in both cases only
one dose of MPEP was tested and no dose-response measurements were performed.
Furthermore, a separate study found that systemic MPEP injections were able to reduce
mechanical hypersensitivity induced by multiple neuropathic pain models (Zhu et al.,
2004), indicating that multiple sensory modalities may be susceptible to modulation by
mGlu5 antagonists following neuropathic injury.
Taken as a whole, the literature suggests that MPEP is analgesic in multiple
nociceptive modalities, and may exert its effects at multiple sites within the pain neuraxis
(Table 1). This would seem to provide strong evidence that mGlu5 plays a prominent role
in pain plasticity. However, suggestions that MPEP may act both as a weak NMDA
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receptor antagonist with micromolar potency (O’Leary et al., 2000; Movsesyan et al.,
2001; Lea and Faden, 2006), and as an inhibitor of the norepinephrine transporter
(Heidbreder et al., 2003), have tempered the enthusiasm that it is functioning exclusively
via mGlu5. The continued quest for highly selective mGlu5 antagonists was greatly
furthered in 2005 by researchers at Hoffman-LaRoche in Switzerland (Porter et al.,
2005). They demonstrated that the non-benzodiazepine anxiolytic fenobam is a potent
and selective negative allosteric modulator of mGlu5 with a chemical structure distinct
from MPEP. This finding was especially exciting as fenobam had previously been tested
in clinical trials in the 1980s where it was found to be an effective anxiolytic with a good
safety profile (Pecknold et al., 1980, 1982; Lapierre and Oyewumi, 1982). However, due
to potential side effects and (during the 80s) an unknown mechanism of action, fenobam
was never pursued as a commercial product.
Interestingly, in addition to its analgesic properties, the mGlu5 antagonist MPEP
has also been demonstrated to have anxiolytic effects (Varty et al., 2005; Ballard et al.,
2005). Furthermore MPEP (Yan et al., 2005), and mGlu5 antagonists in general (Dolen et
al., 2007), have been suggested as potential therapeutics for the treatment of Fragile X
syndrome (FXS). The hypothesis that fenobam would function as a clinical therapeutic
for FXS in humans was recently tested (Berry-Kravis et al., 2009). Fenobam
demonstrated some mild beneficial effects and was found to be without significant
adverse effects in both healthy volunteers and FXS patients . Prior to the work presented
in this thesis, the efficacy of fenobam in the treatment of pain was untested.
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Zhao (2004)
MPEP Reduces CFA-Induced Mechanical Hypersensitivity Walker (2001a)d
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-
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Karim (2001)
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Karim (2001)
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RESULT
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NOXIOUS AGENT ANTAGONIST SPECIES

a) MPEP also results in motor impairment; b) this paper also demonstrated immuno-electronmicroscopy of mGlu5 on unmyelinated nerve terminals in the
skin; c) 50 nmol DHPG induced hypersensitivity, however higher doses were without effect; d) oral MPEP did not impair motor coordination; e) intraplantar
and intrathecal MPEP were without effect; Systemic MPEP is administered i.p.; CFA - complete Freund’s Adjuvant; CCI - Chronic Constriction Injury

Cold Hypersensitivity

Mechanical Hypersensitivity

Heat Hypersensitivity

Spontaneous Nocifensive
Behavior

BEHAVIORAL MEASURE

Table 1: The Effects of mGlu5 Pharmacological Manipulation on Animal Behavioral Models of Pain

Summary of Findings: mGlu5 as a Target for the Treatment of Pain
Both peripheral and central activation of mGlu5 has been suggested to modulate
pain plasticity, and pharmacological antagonism of mGlu5 at peripheral and central sites
has been suggested to be analgesic. It is therefore conceivable that pharmacological
therapeutics designed to modulate mGlu5 would represent viable analgesics in humans.
However, as discussed above, the questionable selectivity of MPEP has prevented the
unambiguous determination of the role that mGlu5 plays in pain.
Direct testing of the necessity of mGlu5 in pain plasticity using genetically
modified animals has not been previously conducted. One of the primary goals of this
thesis was to assess the pain related behaviors of a colony of mGlu5 KO mice as
compared to their WT littermates. This was intended to test directly the assumption that
mGlu5 is required for the full expression of pain-related behaviors, while simultaneously
avoiding the issue of antagonist selectivity. In Chapter 2 I present evidence that mGlu5
KO mice have deficits in several nociceptive behaviors, suggesting that mGlu5 is
required for the full expression of pain.
All previous work involving the study of mGlu5 in pain has been performed using
animal models and other pre-clinical experiments. Future endeavors aimed at the
development of mGlu5 antagonists as analgesics would be aided by an antagonist that has
been shown to be clinically viable and safe in human subjects. Therefore, one of the goals
of this thesis was to test the hypothesis that fenobam is analgesic in rodents, thus
providing the necessary preclinical evidence to proceed with future clinical trials in
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humans. Results from studies suggesting that fenobam is analgesic in rodents are
presented in Chapter 3. Additionally, the demonstration that mGlu5 antagonists are
devoid of analgesic efficacy in mGlu5 KO mice would provide compelling evidence that
they are mediating their analgesic effects by inhibiting mGlu5. Therefore another goal of
this thesis was to assess the analgesic effects of both fenobam and MPEP in mGlu5 KO
mice. Results from these experiments are also presented in Chapter 3.
Finally, future clinical development of mGlu5 antagonists as analgesics will not
only depend on analgesic efficacy, but also a lack of debilitating or dose-limiting side
effects. An assessment of the locomotor and motor-coordination related behaviors of
mGlu5 KO mice as well as the effects of fenobam on these behaviors is presented in
Chapter 4. While mGlu5 KO mice seem to have altered locomotor behavior that is also
induced by fenobam in WT animals, it is possible that these effects may not impede the
development of analgesics as mGlu5 antagonists. One potential way to avoid centrallymediated side effects would be to use peripherally restricted mGlu5 antagonists. As
mentioned above, mGlu5 is expressed throughout the pain neuraxis and both peripheral
and central receptors have been proposed to play a role in pain-related behaviors. Thus
peripheral receptors could theoretically be selectively or preferentially targeted over
central receptors to induce analgesia without inducing centrally mediated side effects.
Unfortunately neither the precise role of peripheral mGlu5 in pain, nor the existence of
any peripherally restricted mGlu5 antagonists needed to test this hypothesis, are presently
known. In order to assess the necessity of peripheral mGlu5 in pain I sought to test the
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pain related behaviors of a colony of mice in which mGlu5 has been selectively deleted
only from peripheral nociceptors. In Chapter 5 I present findings that suggest that
peripherally restricted mGlu5 KO mice do not have alterations in their pain related
behaviors. While this decreases enthusiasm for the development of peripherally restricted
mGlu5 antagonists as analgesics, taken together the bulk of the data presented in this
thesis suggest that antagonism of mGlu5 may represent a viable therapeutic option for the
treatment of pain in humans.
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Chapter 2
The Pain Related Behaviors
of mGlu5 KO Mice
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INTRODUCTION
As discussed above, mGluRs modulate neurotransmission by coupling to
intracellular signaling cascades (Niswender and Conn, 2010). In addition to playing
important roles in synaptic plasticity, learning and memory, anxiety, and other
neurological disorders, mGlu5 is expressed at synapses throughout the pain neuraxis
(Varney and Gereau, 2002) where it has been shown to play a role in the modulation of
multiple

nociceptive

modalities.

mGlu5

agonists

induce hypersensitivity when

administered both peripherally and centrally (Bhave et al., 2001, Kolber et al., 2010), and
intrathecal injections cause spontaneous nociceptive behaviors in mice (Karim et al.,
2001). Conversely mGlu5 antagonists have analgesic effects when delivered systemically,
(Zhu et al., 2004; Walker et al., 2001a) intrathecally, (Karim et al., 2001), and
peripherally (Bhave et al., 2001; Walker et al., 2001b; Zhu et al., 2005). However, there is
some controversy regarding the selectivity of these antagonists, and suggestions have
been made that their analgesic effects are not mediated entirely by mGlu5 (O’Leary et al.,
2000; Movsesyan et al., 2001; Lea and Faden, 2006). The issue of antagonist selectivity
will be directly addressed in chapter 3. Here I sought to circumvent the issue of
antagonist selectivity by using a genetic strategy to test the role of mGlu5 in pain. In this
section I present data from mouse pain models used to assess the nociceptive behaviors of
mGlu5 KO mice (Jia et al., 1998) and their WT littermates. These mice were generated in
the lab of John Roder at the Samuel Lunenfeld Research Institute in Toronto, Ontario. A
0.4-kb fragment containing a portion of exon 1 and intron 1 was deleted and replaced
with a 1.8-kb fragment containing a PGK-neomycin cassette.
34

	


I used a battery of inflammatory and neuropathic pain models, including DHPG-

and Complete Freund’s Adjuvant (CFA)-induced hypersensitivity, spontaneous formalin
behavior, and both chronic constriction injury- and spared nerve injury-induced
hypersensitivity. I have found that mGlu5 deficient mice have reduced responses in
multiple pain behavioral models.
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METHODS
Animals: Experiments were performed in accordance with the guidelines of the National
Institutes of Health and were approved by the Animal Care and Use Committee of
Washington University School of Medicine. mGlu5 KO mice (6 to 8 weeks old) were
bred inhouse on a C57BL/6 background and compared to WT littermates (Jia et al.,
1998). Blinding to genotype was accomplished by using coded ear tag identification
numbers and only breaking the code at the end of the experiment. Unless otherwise
specified only male mice were tested. All mice were group housed on a 12/12-light/dark
schedule with lights on at 0600 CST and ad libitum access to food and water.

PCR Genotyping: Genotyping of mice bred inhouse was performed using standard PCR
techniques with primers targeted to exon 1 of the mGlu5 locus. Three primers were used,
a forward oriented common primer upstream of the deleted segment, and two reverse
primers  a WT primer within the deleted segment, and a KO primer within the
neomycin cassette.

Primers:
1) Common Primer  oIMR1034  CAC ATG CCA GGT GAC ATC AT
2) Wild Type Primer  oIMR1035  CCA TGC TGG TTG CAG AGT AA
3) Knock Out Primer  oIMR2060  CAC GAG ACT AGT GAG ACG TG
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Genotyping Reaction Master Mix (per reaction):
1) MilliQ Water: 8.4 µl
2) GoTaqFlexi (Promega) 5x Buffer: 4 µl
3) MgCl2 (25 mM): 2 µl
4) WT Primer: 1 µl
5) Common Primer: 2 µl
6) KO Primer: 1 µl
7) dNTPs (10 mM): 0.4 µl
8) GoTaq (Promega): 0.2 µl
9) Extracted Tail DNA: 1 µl

PCR Protocol:
Cycle 1 (1x): Step 1: 94oC for 3 minutes
Cycle 2 (35x): Step 1: 94oC for 30 seconds
Step 2: 62oC for 45 seconds
Step 3: 72oC for 45 seconds
Cycle 3 (1x): Step 1: 72oC for 2 minutes
Hold at 4oC until agarose gel separation

Gel Separation: PCR product separation on a 1.5% agarose gel yields 2 bands, a KO
band at ~650 bp, and a WT band at ~440 bp. Heterozygous animals have both bands.
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Immunohistochemistry: WT and mGlu5 KO littermate mice were deeply anesthetized
with a 100 µl injection of ketamine, acepromizine, and xylazine (KAX) (42.86 mg/ml,
8.57 mg/ml, and 1.43 mg/ml KAX respectively), then perfused transcardially with 0.5%
procaine in PBS (37oC), followed by 20 ml of ice-cold 4% paraformaldehyde dissolved in
PBS. The brain and spinal cord were dissected immediately and cryoprotected overnight
in 30% sucrose dissolved in PBS. Tissue samples were mounted in Sakura Tissue-Tek
O.C.T. Compound (VWR) and frozen on dry-ice and then stored at -80oC until
sectioning. Coronal sections (30 µm) were made on a cryostat and refrigerated in PBS
(4oC) until immunostaining. All steps described below were carried out while gently
rocking on an orbital shaker. All steps were carried out at room temp except for primary
incubation. Sections were washed three times for 5 minutes each in 0.1 M PB, incubated
in 0.3% H2O2 and 10% methanol in 0.1 M PB for 30 min, then washed again in 0.1 M PB
(3 times, 5 min each). Sections were blocked for 2 hours in normal goat serum and 0.3%
Triton-X (Sigma-Aldrich, St. Louis, MO), then incubated overnight at 4oC in rabbit antimGlu5 (1:3K, Millipore, Cat. # 06-451) dissolved in blocking solution. The next day
sections were washed three times for 10 minutes each in 0.1 M PB, and incubated in goat
anti-rabbit conjugated to Alexa Fluor 488 (1:1K, Invitrogen). Finally sections were rinsed
again in 0.1 PB (3 times, 10 min each), wet mounted, and imaged on an Olympus BX51
compound fluorescent microscope. Exposure times used for WT and KO tissue samples
were identical and are reported in the results.
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Reagents and Drugs used in Behavioral Experiments: (RS)-3,5dihydroxyphenylglycine (DHPG) was purchased from Tocris (Ellisville, MO) and
dissolved in 0.9% normal saline on the day of the experiment. Complete Freund’s
Adjuvant (CFA), formalin, and acetone were purchased from Sigma-Aldrich (St. Louis,
MO). Formalin was diluted in 0.9% normal saline on the day of the experiment.

General behavioral testing conditions: All behavioral tests were conducted by an
observer blind to genotype, in a room that was isolated from other activity, and in the
presence of white noise. Room temperature was approximately 25oC. Mice were
acclimated to the testing environment starting 2 to 3 hours after the beginning of the light
cycle. Acclimation was always performed for >2 hours prior to any behavioral testing. All
paw injections were subcutaneous, and were made into the plantar surface of the right
paw.

Intraplantar DHPG-Induced Heat Hypersensitivity: Heat thresholds were measured
using a modified Hargreaves’ test (Hargeaves

et

al., 1988). Mice were placed in

individual transparent Plexiglas boxes (10L x 10W x 15H cm) on an elevated glass
platform. A continuous radiant heat source was delivered through the glass onto the
surface of each hind paw (IITC Life Sciences, Woodland Hills, CA), and the latency for
animals to withdraw their paw from the glass surface was measured. The idle intensity of
the heat source was set to 2% and the active intensity was set to 15% with a 20-second
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cutoff. Baseline measurements were collected one day before collecting hypersensitivity
measurements and animals were habituated to the testing environment separately on each
day. For measurement of baseline thresholds 5 individual measurements were made per
paw and averaged. Hypersensitivity was created by right hindpaw subcutaneous injection
of 50 nmols of DHPG dissolved in normal saline. The injection volume was 10 µl of
5mM DHPG solution. Withdrawal latencies were measured at 15, 30, 45, 60, 75, 90, 105,
120, 150, 180, 210, and 240 minutes. Every two measurements were averaged to create
one time point (e.g. 15 min. and 30 min. were averaged as the 30 min. time point, etc.).

Intrathecal DHPG-Induced Spontaneous Behavior: Mice were placed in individual
transparent Plexiglas boxes (35L x 25W x 25H cm) on an elevated glass platform. DHPG
(50 nmols dissolved in normal saline) was injected intrathecally into the lumbar spinal
cord at the level of the iliac crest using a Hamilton syringe and a 30 gauge needle. The
injection volume was 5 µl of a 100 mM DHPG solution. The total time spent in
spontaneous nocifensive behavior, defined as caudally oriented licking of the flanks,
hindpaws, or tail, was scored in 5 minute intervals for 15 minutes following DHPG
injection.

Spontaneous Formalin-Induced Nocifensive Behavior: Mice were placed in
transparent Plexiglas boxes (10L x 10W x 15H cm) on a glass surface and 10 µl of 2%
dilute formalin solution (Sigma-Aldrich, St. Louis, MO) was injected subcutaneously into
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the plantar surface of the right hind paw. The time spent in nocifensive behavior, defined
as licking, lifting, or flicking of the injected paw, was scored in five-minute intervals for
60 minutes after paw injection.

Complete Freund’s Adjuvant (CFA)-Induced Heat Hypersensitivity: Heat thresholds
were measured using a modified Hargreave’s apparatus in the same manner as described
for DHPG-induced heat hypersensitivity. Baseline measurements were collected one day
before collecting hypersensitivity measurements and animals were habituated to the
testing environment separately on each day. For measurement of baseline thresholds 5
individual measurements were made per paw and averaged. CFA-induced
hypersensitivity was created by subcutaneous injection of 10 µl of CFA (Sigma-Aldrich,
St. Louis, MO; 1 mg/ml) into the right paw. Withdrawal latencies were measured at 30,
60, 90, 120, 150, and 180 minutes, and 1, 2, 4, and 7 days. For time points minutes after
injection individual measurements were made. For time points days after injection, 5
independent measurements were averaged.
Measurement of CFA-Induced Mechanical Thresholds: Mechanical sensitivity was
measured using nylon von Frey filaments (North Coast Medical, San Jose, CA). Mice
were habituated in individual transparent Plexiglas boxes (10L x 10W x 15H cm) on an
elevated wire mesh surface. Starting with the smallest filament (0.008 g), successively
larger filaments were applied to the mouse’s hindpaw between the anterior and posterior
foot pads. The smallest filament that evoked responses in 3 out of 5 applications was
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taken as the mechanical threshold for each trial. Baseline measurements were collected
one day before collecting hypersensitivity measurements and animals were habituated to
the testing environment separately on each day. For measurement of baseline thresholds 3
individual measurements were made per paw and averaged. For CFA-induced
hypersensitivity 10 µl of CFA (Sigma-Aldrich, St. Louis, MO; 1 mg/ml) was injected into
the right paw and withdrawal latencies were measured at 1, 2, and 3 hours, and 1, 3, 5,
and 7 days. For time points hours after injection individual measurements were made. For
time points days after injection, 3 independent measurements were averaged.
Chronic Constriction Injury Model: Mice were placed in individual transparent
Plexiglas boxes (10L x 10W x 15H cm) on a wire mesh and spontaneous nocifensive
behavior following the application of one drop of acetone applied to each hindpaw using
a 1 ml syringe was measured for one minute post application. Two measurements were
taken per paw and averaged with at least 5 minutes between applications. Spontaneous
nocifensive behavior was defined as licking, shaking, or lifting of the hindpaw to which
acetone was applied. Hypersensitivity to acteone was induced via chronic constriction
injury of the sciatic nerve using a modified version of the model developed by Bennett
(Bennett & Xie, 1988) Briefly, one day after baseline measurements mice were
anesthetized with a combination of ketamine, acepromizine, and xylazine (KAX)
(114mg/kg, 1.14 mg/kg, and 5.76 mg/kg KAX respectively), a small incision in the left
thigh was made, and the sciatic nerve was exposed. Two loose ligatures of 6-0 chromic
gut suture were tied around the sciatic nerve one millimeter apart. The wound was
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irrigated with sterile saline and closed with 6-0 silk suture. Animals were allowed to
recover for 3 days, then spontaneous nocifensive behavior to acetone was determined as
described above. Acetone-induced nocifensive behavior was measured 3, 5, 7, 10, 14, 21,
and 28 days post injury.

Spared Nerve Injury Model: Mechanical hypersensitivity following spared nerve injury
was performed as described previously (Alter et al., 2010). Briefly, mice were placed in
individual transparent Plexiglas boxes (10L x 10W x 15H cm) on a wire mesh and
baseline withdrawal latencies to Von Frey filaments were obtained from the sural nerve
territory (lateral surface of the hindpaw) using the up-down method (Chaplan et al.,
1994). One day after baseline measurements mice were anesthetized with pentobarbital, a
small incision in the thigh was made, and the three main branches of the sciatic nerve
were exposed. The common peroneal and tibial nerves were ligated with 8-0 silk suture
and cut distal to ligation. One millimeter of distal nerve stump was removed, and the
surgical wound was closed with 7 mm surgical clips. After 3 d of recovery, clips were
removed. Withdrawal latency to mechanical thresholds in the sural nerve territory was
obtained 3, 5, 7, 10, 14, 21, and 28 days post injury.

Data Analysis: Statistical analysis of behavioral data was performed using Prism 5.0
(GraphPad Software, Inc.).All data collected over multiple time points from the
spontaneous formalin and DHPG, mechanical and thermal hypersensitivity, and
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neuropathic pain models, were statistically analyzed using a Bonferroni multiple
comparison test after a two-way ANOVA. Summed data from these tests were analyzed
using a two-tailed t-test when comparisons were made between two groups or a
Bonferroni multiple comparisons tests after a one-way ANOVA when comparisons were
made between more than two groups. Comparisons made between 2 groups at one time
point (e.g. baseline thermal withdrawal latencies) were made using a two-tailed t-test. In
all studies, the accepted level of significance was p < 0.05. In all figures data are reported
as mean +/- SEM. Comparisons between baseline and later data points were done as a
one-way ANOVA with a Dunnett’s Multiple Comparison Post Test.
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RESULTS
Verification of mGlu5 Deletion
PCR Genotyping: PCR yielded bands of expected size that were readily separable via
agarose gel electrophoresis (data not shown).
Immunohistochemsistry: IHC of brain and spinal cord slices from WT animal identified
by PCR demonstrated robust mGlu5 immunoreactivity in the CA1 region of the
hippocampus, the dentate gyrus, the striatum, and the dorsal horn of the spinal cord. In
agreement with previous reports (Jia et al., 1998), this immunoreactivity was absent in
animals identified as KOs (Figure 1).
Brain

Spinal Cord

Figure 1: Lack of mGlu5 Protein
Expression in mGlu5 KO Mice.
Anti-mGlu5 immunostaining
demonstrating a lack of mGlu5 in KO
brain and spinal cord. Anti-mGlu5

WT

(1:3K) primary antibody and Alexa 488
(1:1K) secondary. Brain is imaged using
a 4x objective and a ⅓ second exposure.
Spinal cord is imaged using a 4x
objective and a ½ second exposure.

KO
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Baseline Sensitivity of mGlu5 KO Mice to Mechanical and Thermal Stimuli:
Baseline sensitivities to heat as measured using the Hargreaves apparatus (Figure 2a),
evaporative cooling as measured by application of acetone (Figure 2b), and mechanical
sensitivity (Figure 2c) as measured using nylon Von Frey filaments, were not different
between WT and mGlu5 KO mice.

Cold Sensitivity

12
8
4
0
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1.5
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0.5
0.0
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Mechanical
Sensitivity
Withdrawal Threshold (g)

Heat Sensitivity

Licking or Shaking Following
Acetone Application (s)

B

Withdrawal Latency (s)

A

WT KO

1.0
0.8
0.6
0.4
0.2
0.0

WT KO

Figure 2: Baseline Thermal and Mechanical Sensitivity are Not Altered in mGlu5 KO Mice
A) Heat Sensitivity(WT = 8.7 +/- 0.6 sec; KO = 9.7 +/- 0.6 sec; n = 30 per group), B) cold sensitivity (WT
= 1.2 +/- 0.13 sec; KO = 1.2 +/- 0.17 sec; n = 26 per group for WT, 20 per group for KO), and C)
mechanical sensitivity (WT = 0.63 +/- 0.07 g; KO = 0.76 +/- 0.06 g; n = 20 per group) were not altered by
a lack of mGlu5. Data are presented as averages of both paws +/- SEM.
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DHPG-Induced Nocifensive Behaviors are Reduced in mGlu5 KO Mice: Sensitivity
to the group I mGluR agonist DHPG was decreased in KO mice as measured both by
spontaneous nocifensive behavior following an intrathecal DHPG injection (Figure 3a),
and by the development of hypersensitivity to a thermal stimulus following ipsilateral
intraplantar injection of DHPG (Figure 3b). mGlu5 KO mice did not develop thermal
hypersensitivity following DHPG injection, whereas hypersensitivity developed in WT
mice at multiple time points. No changes in thermal sensitivity were observed in the
contralateral paw of either genotype following intraplantar DHPG injection (data not
shown).
Figure 3: DHPG-Induced Spontaneous Nocifensive Behavior and Thermal Hypersensitivity is
Reduced in mGlu5 KO Mice
A) Wildtype mice have significantly greater nocifensive behavior than their KO littermates following
intrathecal DHPG injection (2-Way ANOVA Main Effect of Genotype *** = p=0.0004; n = 4-5 mice per
group). B) Thermal hypersensitivity following DHPG is not observed in mGlu5 KO mice, but is observed
in their WT littermates (2-Way ANOVA Main Effect of Genotype *** = p<0.0001; n = 8 mice per group).
Paw withdrawal latencies of WT mice were significantly decreased from baseline at multiple time points
(1-Way ANOVA Main Effect p=0.02). No time points were significantly different from baseline in KO
mice. Paw withdrawal latencies of the paw contralateral to intraplantar DHPG injection were not
significantly different (2-Way ANOVA Main Effect of Genotype p=0.90). *, **, and *** = p < 0.05, 0.01,
and 0.001 WT compared to KO; †, †† = p<0.05, 0.01 WT time point compared to baseline.
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Formalin-Induced Nocifensive Behavior is Reduced in mGlu5 KO Mice: Nocifensive
behavior, as measured by time spent licking or lifting the injected paw, was significantly
decreased in mGlu5 KO mice as compared to WT littermates (Figure 4a). In addition, the
time spent licking or lifting was significantly decreased when summed from 0 to 10
minutes (Phase 1, Figure 4b) and from 10 to 60 minutes (Phase 2, Figure 4c).
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Figure 4: Decreased Nocifensive
Behavior Following Intraplantar
Formalin Injection in mGlu5 KO Mice.
A) Wildtype mice have significantly
greater nocifensive behavior following

150

intraplantar formalin injection as
compared to their KO littermates (2-Way
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ANOVA Main Effect of Genotype ** =
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Bonferroni post-test ** = p<0.01; n = 5-6

0
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CFA-Induced Nocifensive Behavior is Reduced in mGlu5 KO Mice: Intraplantar CFA
injection induced a unilateral hypersensitivity to mechanical stimuli in both WT and
mGlu5 KO mice. However, in mGlu5 KO mice recovery to baseline levels occurred
within 1 day, whereas WT mice never recovered to baseline levels (Figure 5a). The
duration of hypersensitivity to mechanical stimuli was significantly shorter in mGlu5 KO
mice compared to WT littermates. No hypersensitivity developed to mechanical stimuli
in the contralateral paw of mice from either genotype (data not shown).
Intraplantar CFA injection also induced a unilateral hypersensitivity to thermal
stimuli in both WT and mGlu5 KO mice. This hypersensitivity was shorter lived than that
to mechanical stimuli and both genotypes had recovered to levels not significantly
different from baseline after 120 minutes (WT mice after 60 minutes). Genotype did not
affect the development or recovery from thermal hypersensitivity (Figure 5b). No
hypersensitivity developed to thermal stimuli in the contralateral paw of mice from either
genotype (data not shown).
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Figure 5: CFA-Induced Mechanical Hypersensitivity is Reduced in mGlu5 KO Mice
a) mGlu5 KO mice have significantly faster recovery from CFA-induced mechanical hypersensitivity
compared to their WT littermates (2-Way ANOVA Main Effect of Genotype *** = p<0.0001; n = 10 mice
per group). Paw withdrawal latencies of WT and KO mice were significantly decreased from baseline at
multiple time points (1-Way ANOVA Main Effect p<0.0001 and p=0.0003 respectively). Paw withdrawal
thresholds of the paw contralateral to intraplantar CFA injection were not significantly different (2-Way
ANOVA Main Effect of Genotype p=0.73). b) CFA-induced thermal hypersensitivity was not different in
WT and mGlu5 KO mice (2-Way ANOVA Main Effect of Genotype p=0.86; n = 7 mice per group). Paw
withdrawal latencies of WT and KO mice were significantly decreased from baseline at multiple time
points (1-Way ANOVA Main Effect p=0.01 and p<0.0001 respectively). Paw withdrawal latencies of the
paw contralateral to intraplantar CFA injection were not significantly different (2-Way ANOVA Main Effect
of Genotype p=0.53).
*, *** = p < 0.05, 0.001 WT compared to KO; †, ††† = p<0.05, 0.001 WT time point compared to
baseline; ## , ### = p<0.01, 0.001 KO time point compared to baseline.
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Neuropathic Pain Models in mGlu5 KO Mice: Hypersensitivity to evaporative cooling
was induced in mGlu5 KO mice and their WT littermates as compared to their respective
baselines at all time points measured post chronic constriction injury (Figure 6a).
However hypersensitivity to evaporative cooling was significantly less in mGlu5 KO
mice compared to WT littermates. No hypersensitivity developed to acetone in the
contralateral paw of mice from either genotype (data not shown).
Spared Nerve Injury induced mechanical hypersensitivity in both mGlu5 KO mice
and their WT littermates compared to their respective baselines at all time points
measured post nerve injury (Figure 6b). There were no differences attributable to
genotype. Hypersensitivity was not induced in the paw contralateral to injury (data not
shown).
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Figure 6: Neuropathic Pain in mGlu5 KO Mice
A) mGlu5 KO mice exhibit significantly less licking or lifting following acetone application (2-Way
ANOVA Main Effect of Genotype ** = p<0.01; n = 10 - 13 mice per group). Licking and lifting was
significantly greater than baseline at all time points for both genotypes (WT and KO 1-Way ANOVA Main
Effect p<0.0001 and =0.0002 respectively). B) mGlu5 KO and WT both exhibited mechanical
hypersensitivity after spared nerve injury. No differences were attributable to genotype (2-Way ANOVA
Main Effect of Genotype p=0.80; n = 4 - 6 mice per group). Mechanical sensitivity was significantly less
than baseline at all time points for both genotypes (Both WT and KO 1-Way ANOVA Main Effect
p<0.0001).
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DISCUSSION
The analgesic properties of mGlu5 antagonists have been previously reported
(Bhave et al., 2001; Walker et al., 2001a; Zhu et al., 2004). However unambiguous
determination of the role mGlu5 plays in the development and maintenance of chronic
pain has been hindered by questionable antagonist selectivity. Here I present data from
mGlu5 KO mice that show that mGlu5 is required for the full expression of pain-related
behaviors. When compared to WT littermates mGlu5 KO mice were found to have
reduced nociceptive behaviors in the formalin test and following CFA-induced
mechanical hypersensitivity. These data are in agreement with those from antagonist
studies. Coupled with the findings presented here that the pro-algesic effects of the group
I mGluR agonist DHPG are markedly reduced in mGlu5 KO mice, these findings
strongly support the hypothesis that mGlu5 plays a role in nociception. It is interesting
that baseline sensitivity of mGlu5 KO mice to thermal and mechanical stimuli were
unchanged, suggesting that mGlu5 is only required for the development and maintenance
of hypersensitivity and not normal sensation itself.
Some of the findings from mGlu5 KO mice presented here are at odds with those
obtained from antagonist studies, however. While the results from the formalin test and
the studies of CFA-induced mechanical hypersensitivity recapitulate the effects of MPEP
(Zhu et al., 2004; Walker et al., 2001a), the findings that CFA-induced thermal
hypersensitivity, and mechanical hypersensitivity post-SNI are the same in mGlu5 KO
mice as their wildtype littermates is at odds with results obtained using MPEP (Zhu et al.,
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2004). This may be due to the fact that previous studies using MPEP were conducted
using rats while the studies here use mice; alternatively it could suggest that MPEP’s
analgesic effects are off-target for mGlu5. A direct assessment of the analgesic effects of
MPEP in mGlu5 KO mice is presented in Chapter 3.
The mice described in this chapter have a global deletion of mGlu5. While these
KO mice have reductions in pain-related behaviors, mGlu5 is expressed at synapses
throughout the pain neuraxis (Varney and Gereau, 2002), and the global nature of this
deletion precludes the determination of the relative contribution of mGlu5 expressed at
different synapses to nociceptive signal processing. DHPG is proalgesic when
administered into the periphery, spinal cord, and higher brain structures and MPEP
administration to all of these sites attenuates nociceptive behaviors (Bhave et al., 2001;
Karim et al., 2001; Kolber et al., 2010). Therefore, it is possible that activation of mGlu5
at all levels of the pain neuraxis plays a role in nociception. In Chapter 5 I will report on
findings from mice in which mGlu5 was selectively deleted only in peripheral
nociceptors to test the hypothesis that peripheral mGlu5 is required for the full expression
of pain-related behaviors.
Results from the experiments discussed in this chapter suggest that mGlu5 might
be a druggable target for the treatment of pain. In Chapter 3 I will present data on the
analgesic properties of the mGlu5 antagonist fenobam, which has been tested in human
subjects for the treatment of anxiety. Fenobam has been found to have a good safety
profile, and thus could theoretically represent an mGlu5 antagonist suitable for treating
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pain in human patients. Finally, mGlu5 antagonists will only be useful for the treatment
of human pain conditions if they also have acceptable side-effects profiles. In Chapter 4 I
assess the possibility that antagonism of mGlu5 may affect locomotion and motor
coordination (Zhu et al., 2004), which would unfortunately represent potential deleterious
effects that could reduce the utility of mGlu5 antagonists as analgesics.
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Chapter 3
The mGlu5 antagonist fenobam is
analgesic and has improved in vivo
selectivity as compared to the prototypical
antagonist MPEP.
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INTRODUCTION
As discussed in chapter 2, mGlu5 KO mice have reduced sensitivity to painful
stimuli. Thus, mGlu5 represents a potential molecular target for the therapeutic treatment
of pain. However, past studies of mGlu5 antagonists have been primarily limited to preclinical animal models. Research into the efficacy of mGlu5 antagonists in the treatment
of human pain conditions would be greatly enhanced by an antagonist that has been
shown to be safe and pharmacologically active in humans. Recently, researchers at
Hoffmann-La Roche demonstrated that the clinically validated non-benzodiazepine
anxiolytic fenobam [N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1Himidazole-2-yl)urea] is a highly potent and selective antagonist of mGlu5 (Porter et al.,
2005). McNeil Laboratories originally developed Fenobam as a potential anxiolytic in the
1970s and 80s, but with a then unknown molecular target. It was found to be effective at
treating anxiety in a double-blinded placebo-controlled clinical trial (Pecknold et al.,
1982). In that trial, and two additional trials (Pecknold et al., 1980; Lapierre and
Oyewumi, 1982), fenobam was reported to have a good safety profile with no
oversedation, no muscle relaxation, and no interaction with ethanol. However in a
different phase II clinical trial (Friedmann et al., 1980) fenobam was reported to have
both psychostimulant side effects and be ineffective as an axiolytic. In the early 1980s,
further development of the molecule as an anxiolytic by McNeil was discontinued. Then
in 2005, a functional high-throughput screen and subsequent characterization by Porter, et
al. identified fenobam as a potent, non-competitive, mGlu5 selective antagonist, acting at
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an allosteric modulatory site shared with the prototypical mGlu5 antagonist 2-methyl-6(phenylethynyl)-pyridine (MPEP) (Gasparini et al., 1999). Interestingly, in addition to its
anxiolytic efficacy (Ballard et al., 2005) MPEP has also been reported effective in the
treatment of animal models of both Fragile X syndrome (FXS) (Yan et al., 2005) and
chronic pain (Zhu et al., 2004). Fenobam was recently tested as a potential clinical
therapeutic for FXS in humans, where it was shown to possess beneficial clinical effect
without significant adverse effects (Berry-Kravis et al., 2009). However, the efficacy of
fenobam in the treatment of pain remains untested.
Given the interest in mGlu5 as a target for inflammatory pain and the recent
demonstration of fenobam’s efficacy as a clinically validated mGlu5 antagonist with a
good safety profile, I sought to compare fenobam’s analgesic efficacy to that of MPEP in
several in vivo models of inflammatory pain. Here I show that fenobam, like MPEP, can
prevent formalin-induced spontaneous pain-related behaviors and reduce Complete
Freund’s Adjuvant (CFA)-induced thermal hypersensitivity. In addition, fenobam was
also found to prevent spontaneous pain-related behaviors induced by the algogenic
TRPA1 agonist mustard oil (Jordt et al., 2004). Previous pharmacokinetic analysis of
fenobam in humans has indicated variable plasma levels (Berry-Kravis et al., 2009), thus
I also sought to characterize the bioavailability of fenobam in both mouse plasma and
brain tissue. Studies were also tested to determine whether tolerance to the analgesic
effects of fenobam develop following repeat dosing. In order to establish selectivity for
its analgesic effects on mGlu5, I also assessed the pain behaviors of mGlu5 KO mice that
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were treated with either fenobam or MPEP. Finally, as will be discussed in detail in
Chapter 4, I also assessed fenobam in a battery of tests designed to look for potential
undesirable effects.
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METHODS
Animals: Experiments were performed in accordance with the guidelines of the National
Institutes of Health and were approved by the Animal Care and Use Committee of
Washington University School of Medicine. Male Swiss-Webster mice (29.5 – 43 g) were
purchased from Taconic. Male C57BL/6 mice used in metabolism experiments (20.0 –
29.5 g) were purchased from Jackson Labs. For experiments involving mice lacking
mGlu5 (mGlu5 KO; 16.5 – 22.5 g), animals were bred inhouse on a C57BL/6
background and compared to WT littermates (Lu et al., 1997). For experiments involving
KO animals the experimenter was blinded to genotype. All other C57BL/6 WT mice
used in behavioral experiments were also derived from this colony. Blinding to genotype
was accomplished by using coded ear tag identification numbers and only breaking the
code at the end of the experiment. Genotyping of mice bred inhouse was performed using
standard PCR techniques as described in Chapter 2. All mice were group housed on a
12/12-light/dark schedule with ad libitum access to food and water.

Chemicals and Reagents: Fenobam and MPEP were purchased from Tocris (Ellisville,
MO). Both compounds were dissolved in DMSO (100%) (Sigma-Aldrich, St. Louis, MO)
on the day of experiment. All intraperitoneal (i.p.) injection volumes were 20 microliters.
Throughout all experiments the investigator was blinded to pharmacological treatment.
Midazolam was purchased from Cerilliant (Round Rock, TX) and used as the HPLC/MS
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internal standard.

All other reagents were HPLC grade and purchased from Sigma-

Aldrich Co. (St. Louis, MO).

General behavioral testing conditions: Behavioral tests were conducted in the same
general manner as described in Chapter 2.

Spontaneous Formalin-Induced Nocifensive Behavior: Mice were acclimated in a
transparent Plexiglas box (25L x 13W x 13H cm) for 2 hours prior to any drug injection.
Animals were then pretreated by i.p. injection with vehicle, MPEP, or fenobam. All Swiss
Webster mice were pretreated 30 minutes prior to formalin injection. Strain differences in
responsiveness to fenobam were noted in pilot studies and thus C57BL/6 mice were
initially pretreated either 5 or 30 minutes prior to formalin injection to determine the
optimal time for pretreatment in this strain (n = 4-5 per group). In all subsequent formalin
tests involving C57BL/6 mice, including those performed with mGlu5 KO mice, vehicle
or drugs were injected 5 minutes prior to formalin injection. Ten microliters of dilute
formalin solution (Sigma, St. Louis, MO) was injected subcutaneously into the plantar
surface of the right hind paw. Due to strain differences in formalin sensitivity (Mogil et
al., 1999), the concentration of formalin injected into Swiss-Webster mice and C57BL/6
mice was 5% and 2% respectively. The time spent in nociceptive behavior, defined as
licking, lifting, or flicking of the injected paw, was scored in five-minute intervals for one
hour beginning immediately after paw injection. For experiments comparing fenobam to
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MPEP in Swiss Webster mice, 30 mg/kg of each drug was administered (n=7 per group).
For experiments intended to develop a dose response curve for fenobam in Swiss Webster
mice, 3, 10, 30, or 100 mg/kg of fenobam was injected (n = 7-11 per group).

For

experiments involving the testing of fenobam in C57BL/6 WT and mGlu5 knockout mice
30 mg/kg of fenobam was injected (n=4-6 per group). For experiments involving the
testing of MPEP in mGlu5 KO mice 30 mg/kg MPEP was injected (n = 6-9 per group).

Spontaneous Formalin-Induced Nocifensive Behavior following Chronic Fenobam
Treatment: Male Swiss Webster mice mice were injected i.p. once per day for 5 days
with 30 mg/kg of fenobam or vehicle (DMSO). On the 6th mice were placed in
transparent Plexiglas boxes (10L x 10W x 15H cm) on a glass surface and mice from
each group (chronic fenobam and chronic vehicle) were both injected with either
fenobam or vehicle, followed 5 minutes later by intraplantar formalin injection. Thus,
eight separate groups were analyzed, 1, 2) chronic vehicle / acute vehicle; 3, 4) chronic
fenobam / acute vehicle; 5, 6) chronic vehicle, acute fenobam; 7,8) chronic fenobam,
acute fenobam; with chronicity defined as 5 days. The time spent in nocifensive behavior
was scored in five-minute intervals for 45 minutes after paw injection as described above.

Spontaneous Mustard Oil-Induced Nocifensive Behavior: Mustard oil-induced
nocifensive behavior was performed in the same manner as that described for the
formalin test, except 0.5% mustard oil was injected subcutaneously instead of formalin.
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In addition, behavioral responses were only scored for 30 minutes post mustard oil
injection. Fenobam (30 mg/kg) or vehicle (DMSO) were injected 30 minutes prior to
scoring mustard-oil induced behaviors (n= 4 per group).

Complete Freund’s Adjuvant (CFA) Induced Thermal Hypersensitivity: Thermal
hypersensitivity was measured in a manner similar to that described in Chapter 2. Briefly,
Swiss Webster (n = 8 per group) mice were placed in individual Plexiglas containers
(10L x 10W x 15H cm) on an elevated glass platform. A continuous radiant heat source
was delivered through the glass onto the surface of each hind paw (IITC Life Sciences,
Woodland Hills, CA), and the latency for animals to withdraw their paw was measured.
The active intensity of the heat source was set to 21%. Five baseline measurements were
obtained 15 minutes apart and averaged. Immediately following baseline CFA (10
microliters; 1 mg/ml) was injected into the plantar surface of the right hind paw. Paw
withdrawal latency to the thermal stimulus (PWLThermal) was assessed 48 hours after CFA
injection. One hour following assessment of post-CFA PWLThermal, animals were injected
i.p. with fenobam (30 mg/kg) or vehicle. PWLThermal was then assessed 30 and 60 minutes
post drug injection.

Data Analysis: Statistical analysis of behavioral data was performed in the same manner
as described in Chapter 2.
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Method for Quantification of Fenobam in Mouse Brain and Plasma
Plasma and Brain Tissue Collection: Wild type Swiss Webster and C57BL/6 (n = 4 per
group) mice were injected with fenobam (3, 10, or 30 mg/kg, i.p.) and administered an
overdose of sodium pentobarbital (75 mg/kg) 5, 30, or 55 minutes after fenobam
injection. Whole blood was obtained by transcutaneous cardiac puncture and plasma was
separated via centrifugation (5 min, 4 °C, 14K G) in plasma separator tubes with lithium
heparin (BD Microtainer). Immediately post centrifugation plasma was frozen using
liquid nitrogen and stored at -80 °C. Brains were dissected and immediately frozen in
liquid nitrogen and stored at -80 °C. Whole brain homogenates were obtained by adding
milliQ water to brain tissue in a 2:1 (v:w) ratio and sonicating using a Branson Sonifier
150. Brain homogenates were immediately refrozen on dry ice.

General Instrumentation: Fenobam was quantitated using LC/MS/MS. Calibrators were
prepared in a matrix matching the samples (brain homogenates or plasma). Midazolam
was used as the internal standard. Instrumental analysis was performed on an API
4000QTRAP triple-quadropole mass spectrometer (Applied Biosystems/MDS Sciex,
Foster City, CA, USA), equipped with a Turbo IonSpray Source. The Agilent 1100 HPLC
system (Waldbronn, Germany) included a binary pump, a thermostatted well-plate
autosampler, and a column thermostat. An external two-way Valco valve was utilized to
direct HPLC flow to waste before and after column elution of analytes of interest.
Chromatographic separation was performed on a SymmetryShield RP18 analytical
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(3.5µm, 2.1 x 30mm) column (Waters Corp., Milford, MA, USA) with a C18 guard
(5µm, 2 x 10mm) column (Varian, Lake Forest, CA, USA) at 30oC. Before each
injection, the needle was washed with methanol. Separate methods were used for
determining fenobam in brain tissue and plasma.

HPLC and Mass Spec Conditions for Quantification of Fenobam in Brain Tissue: Mobile
phase A was 20mM ammonium formate buffer, pH 5.7 and mobile phase B was
methanol. Mobile phase was delivered at an initial condition of 2% B and a flow rate of
0.5ml/min with the following time program: 2% B is held for 0.1 minute, followed by a
linear gradient to 100% B between 0.1 and 1.0 minute. B is held at 100% for 0.1 minute,
and then brought back down to initial condition of 2% between 1.1 and 2.1 minutes. The
column is re-equilibrated with 2% B from 2.1 to 5.0 minutes. Under these conditions, the
retention time for fenobam was 3.3 minutes and for midazolam was 3.4 minutes. The
injection volume was 10 microliters. Both Q1 and Q3 quadrupoles of the mass
spectrometer were optimized to unit mass resolution, and the conditions were optimized
for each analyte. The instrument was operated in positive-ion mode with an ion spray
voltage of 5500 volts. The curtain gas was set at 20 psi, ion source gas 1 and 2 at 20 psi,
and the collision gas on “high”. The transitions monitored for each analyte, along with
the analyte specific parameters are listed in Table 1.
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Calibration and Sample preparation: 50 microliters of each homogenized sample was
pipetted into discrete wells of a 96-well 2.2ml plate. Twenty-five microliters of internal
standard (12.5ng midazolam) was added to each sample, followed by 200 microliters of
acetonitrile. The plate was capped and vortexed, and then centrifuged at 3000 rpm for 10
minutes. The supernatants were transferred to a 96-well autosampler plate, and 10
microliters was injected. Calibrators and quality control samples were prepared along
with experimental samples.

Calibrators, quality controls and internal standard samples: A methanolic solution of
fenobam was prepared at 1mg/mL. Dilutions from this stock standard were prepared and
used to make calibrator and quality control (QC) samples in brain homogenate. Brain
homogenate calibrators contained 0.5, 2.5, 5, 10, 15, 20, 30 and 40µg/g. Brain
homogenate QCs were made at 2.5 and 20µg/g.

HPLC and Mass Spec Conditions for Quantification of Fenobam in Plasma: Mobile
phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in
acetonitrile. Mobile phase was delivered at an initial condition of 5% B and a flow rate of
0.4ml/min with the following time program: linear gradient between 5 and 60% B for 1.0
minute followed by a sharp gradient to 100% B for 0.2 minute and hold at 100% B for
0.4 min; mobile phase composition is then brought back down to initial condition of 5%
between 1.6 and 2.1 minutes. The column is re-equilibrated with 5% B from 2.1 to 5.5
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minutes. Under these conditions, the retention time for fenobam was 3.4 minutes and for
midazolam was 3.0 minutes. The injection volume was 20 microliters. Both Q1 and Q3
quadrupoles of the mass spectrometer were optimized to low and unit mass resolution
respectively. The instrument was operated in positive-ion mode with an ion spray voltage
of 5100 volts. The curtain gas was set at 20 psi, ion source gas 1 and 2 at 40 and 50 psi
respectively, and the collision gas on high. The transitions monitored for each analyte,
along with the analyte specific parameters are listed in Table 2.

Calibration and Sample preparation: Mouse plasma samples were thawed, homogenized
and aliquots of 25 microliters were transferred into a 96-well plate. Precipitation was
performed using 100 microliters of acetonitrile, which contained 50ng/ml of midazolam
(internal standard). The plate was capped and vortexed, and then centrifuged at 3000 rpm
for 10 minutes. The supernatants were transferred to a 96-well autosampler plate, and 20
microliters were injected for analysis. Calibrators and quality control samples were
prepared along with experimental samples.

Calibrators, quality controls and internal standard samples: A methanolic solution of
fenobam was prepared at 1mg/ml. Dilutions from this stock standard were prepared and
used to make calibrator (6.0 to 16,000 ng/ml, 10 concentrations) and quality control (QC)
samples (2 concentrations) in human plasma. Preliminary experiments using mouse and
human plasma had similar LC/MS/MS results.
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Table 1: HPLC-mass spectrometric acquisition parameters for brain tissue
Q1 Mass Q3 Mass Time
amu
267.1
114
267.1
140
326.2
249.3
326.2
291.2

ms
150
150
150
150

Declustering
Potential

Exit Potential

76
76
126
126

10
10
10
10

Collision
Energy
V
21
25
53
37

Collision Cell Exit
Potential
18
22
16
6

Table 2: HPLC-mass spectrometric acquisition parameters for plasma
Q1 Mass Q3 Mass Time
amu
267.1
114
267.1
140
326.2
223.2
326.1
291.2

ms
30
30
30
30

Declustering
Potential

Exit Potential

76
76
90
90

10
10
10
10
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Collision
Energy
V
21
25
50
40

Collision Cell Exit
Potential
18
22
16
14

RESULTS
Effects of Fenobam and MPEP on Spontaneous Formalin Behavior in WT Mice: I
compared the effects of fenobam to MPEP, an mGlu5 antagonist that has been previously
demonstrated to reduce spontaneous behavior during the formalin test. Right hind paw
injection of formalin resulted in a characteristic biphasic response (Figure 1a). Pretreatment with both fenobam (30 mg/kg i.p.) and MPEP (30 mg/kg i.p.) significantly
reduced the time Swiss Webster mice spent licking or lifting the formalin injected paw
during the second phase (Figure 1c). In addition pre-treatment with fenobam resulted in a
reduction in the time spent licking or lifting during the first phase (Figure 1b).
I next examined the effects of four different doses of fenobam (3, 10, 30, and 100
mg/kg i.p.) on nociceptive scores during the formalin test (Figure 2a). Pre-treatment of
Swiss Webster mice with 30 and 100 mg/kg fenobam 30 minutes prior to intra-plantar
formalin injection significantly reduced the time mice spent licking or lifting the injected
paw during both the first (Figure 2b) and second phase (Figure 2c).
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Figure 1: Spontaneous formalin behavior is reduced following pretreatment with fenobam or
MPEP in Swiss Webster mice.
A) When administered 30 min prior to intraplantar formalin injection both Fenobam (30 mg/kg, i.p.) and
MPEP (30 mg/kg, i.p.) significantly decrease the time spent licking or lifting the injected paw (2-Way
ANOVA Main Effect of Drug p< 0.0001). Asterisks indicate time points where both drug treatments are
significantly different from vehicle (n = 7 per group; *, **, *** = p< 0.05, 0.01, 0.001 respectively).
Fenobam treated animals were significantly different from MPEP at the 5 min time point († = p < 0.05)
B, C) Total time spent licking or lifting in the first (0-10 minutes; 1-Way ANOVA Main Effect of drug
p=0.0018) and second phase (10-60 minutes; 1-Way ANOVA Main Effect of drug p=0.0033)
respectively.
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The C57BL/6 strain of mice is often used in the generation of KO animals, and it
is the background strain of the mGlu5 KO mice that I used in this thesis. I therefore
examined the effects of fenobam on spontaneous formalin behavior in this strain. In
Swiss Webster mice pretreatment with fenobam was performed 30 minutes prior to
formalin injection. When C57BL/6 mice were pretreated with fenobam (30 mg/kg) 30
minutes prior to formalin injection there was a reduction in formalin-induced
spontaneous behavior 20 minutes after formalin injection as compared to vehicle,
however the total time in the second phase was not found to be different. When C57BL/6
mice were instead pre-treated with fenobam 5 minutes prior to formalin injection a
significant reduction in the second phase was observed as compared to both vehicle
injected mice and mice injected with fenobam 30 minutes prior to formalin injection
(Figure 3).
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Figure 3: Spontaneous formalin
b e h a v i o r i s re d u c e d f o l l o w i n g
pretreatment with fenobam in WT
C57BL/6 mice.
A) When administered 30 minutes prior
to intraplantar formalin injection
fenobam (30 mg/kg, i.p.) significantly
decreased the time spent licking or
lifting the injected paw as compared to
vehicle at 20 minutes post injection (2Way ANOVA Main Effect of Fenobam
p=0.0007; † = p<0.05). The overall time
spent licking or lifting in the second
phase was not reduced. When fenobam
(30 mg/kg, i.p.) was injected 5 minutes
prior to formalin hind-paw injection
there was a significant reduction at A)
multiple time points (*, *** = p<0.05,
0.001) and C) in the total time spent
licking or lifting in the second phase
(10-60 minutes; 1-Way ANOVA Main
Effect of drug p<0.0015; Bonferroni Post
Test p< 0.01) as compared to both
vehicle and animals injected with
fenobam 30 minutes prior to formalin
injection (n = 4-5 per group).

Effects of Fenobam on Spontaneous Mustard Oil-Induced Behavior in WT Mice:
Mustard oil (allyl isothiocyanate), the pungent component in wasabi and horseradish, is a
potent and selective agonist of the cation channel TRPA1 (Jordt et al., 2004). Right
hindpaw injection elicited spontaneous licking and flinching behaviors that were
significantly reduced by 30 minute pretreatment with 30 mg/kg fenobam (Figure 4).
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Figure 4: Spontaneous Mustard Oil-induced Behavior is Reduced by Fenobam Pretreatment
Pretreatment with fenobam (30 mg/kg i.p.) reduces spontaneous licking and lifting induced by intraplantar
injection of 0.5% mustard oil (n=4 per group). Fenobam or vehicle (DMSO) was injected 30 min prior to
MO. injection. (2-Way ANOVA Main Effect of Fenobam p < 0.0001; Bonferroni Post-hoc test *** = p <
0.001)
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Fenobam Reverses CFA-Induced Thermal Hypersensitivity in WT Mice: The effects
of fenobam and vehicle on CFA induced thermal hypersensitivity were compared. Fortyeight hours following injection of CFA into the right hind paw, paw withdrawal latency to
a thermal stimulus (PWLThermal) relative to baseline was significantly reduced ipsilateral
to the injection in both groups (Fig. 5). No reduction in PWLThermal was observed in the
contraleral paw in either group. One hour following assessment of the 48-hour-post-CFA
PWLThermal, mice were injected i.p with vehicle or fenobam (30 mg/kg). Fenobam, but not
vehicle, significantly increased PWLThermal measured 30 and 60 minutes following drug
injection as compared to their respective 48-hour-post-CFA time point (Figure 5). In the
fenobam treated animals the post-drug PWLThermal returned to a level that was not
significantly different from baseline, however the PWLThermal of the vehicle treated
animals remained significantly different from baseline 30 minutes after vehicle injection
(Figure 5). No differences were observed in the contralateral paw of any group between
baseline, pre-drug, or post-drug PTWLThermal (data not shown).
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Figure 5: Fenobam relieves established CFA-induced thermal hypersensitivity.
Paw withdrawal latency to a thermal stimulus was reduced 48 hours after an ipsilateral CFA injection, as
compared to baseline. Fenobam, but not vehicle, significantly increased thermal withdrawal latency 30 and
60 minutes after treatment in the ipsilateral paw. (1-Way ANOVA Main Effect of Veh p = 0.0039; Main
Effect of Fenobam p = 0.0031; * = p<0.05 both groups as compared to baseline; †,†† = p< 0.05, 0.01
Fenobam as compared to 48 hours post CFA; n = 8 per group).
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Fenobam Disposition in Plasma and Brain Tissue: Fenobam disposition was examined
in both brain and plasma from C57BL/6 and Swiss Webster mice. Fenobam was readily
detectable in plasma and brain tissue five minutes after i.p. injection in both strains
(Figure 6a,b), and concentrations decreased thereafter. Fenobam (3 and 10 mg/kg) was
largely cleared from both plasma and brain tissue after 30 minutes, while the highest dose
(30 mg/kg) remained detectable 30 minutes after injection, but was largely cleared after
55 minutes. A brain:plasma ratio (g/g / g/ml) was calculated for the 5 minute time point
for all three doses (Figure 6c), and was found to be significantly different in both strains
when the 3 mg/kg and 30 mg/kg dose were compared.
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Figure 6: Fenobam brain and plasma
concentrations.
Swiss Webster and C57BL/6 mice were
injected with either 3, 10, or 30 mg/kg
fenobam i.p. and then sacrificed 5, 30, or 55
minutes later. (a) Plasma and (b) brain
fenobam concentrations for each animal, dose,
and time point. (c) A brain:plasma ratio (ml/g)
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Effects of Fenobam and MPEP on Spontaneous Formalin Behavior in mGlu5 KO
Mice: The effects of fenobam and MPEP on spontaneous formalin behavior were
assessed in mGlu5 knockout mice in the same manner as described for Swiss Webster
WT mice. As KO mice were bred on a C57BL/6 background, the effects of fenobam (30
mg/kg) were also assessed on litermate WT mice. Pre-treatment with fenobam (30 mg/kg,
i.p. 5 min. prior to formalin injection) significantly reduced the time WT littermates spent
licking or lifting the formalin injected paw in both the first phase and second phase
(Figure. 7 a-c). However, pretreatment with fenobam (30 mg/kg, i.p) did not alter
spontaneous nociceptive behavior following formalin injection in mGlu5 KO mice at any
time point (Figure 7 d-f). When mGlu5 KO mice were pre-treated with MPEP (30 mg/
kg, i.p.), there was a significant reduction in the time spent licking or lifting the formalin
injected paw in the second phase, but not the first (Figure 7 g-i).
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Figure 7: Spontaneous Formalin Behavior is Reduced by MPEP, but not Fenobam in mGlu5 KO
Mice.
In C57 WT mice (a-c), but not mGlu5 KO litermates (d-f), fenobam (30 mg/kg i.p.) administered 5 min
prior to intraplantar formalin injection significantly decreased the time spent licking of lifting the injected
paw (2-way ANOVA Main Effect of Fenobam *** = p < 0.0001 in WT; p = 0.8513 in KO; Bonferroni Posthoc test *** = p < 0.001). Pretreatment with fenobam reduced both the first (unpaired t-test ** = p =
0.0082) (b) and second (unpaired t-test p=0.049) (c) phases in WT mice. (n = 4-6 per group.) MPEP (g-i)
(30 mg/kg, i.p.) also reduced formalin behavior in mGlu5 KO mice when administered 30 min prior to
intraplantar formalin injection (2-way ANOVA Main Effect of MPEP *** = p = 0.0004). Asterisks indicate
time point where MPEP is significantly different from vehicle (n = 6-9 per group; Bonferroni Post-hoc test
* = p < 0.05). Pretreatment with MPEP reduced the second phase (unpaired t-test *** = p=0.0009) (i) but
not the first (unpaired t-test p=0.18) (i).
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Tolerance Does not Develop to the Analgesic Effects of Fenobam: To test whether
tolerance to the analgesic effects of fenobam develops over time I injected mice with
either vehicle or fenobam (30mg/kg) for five days and then on the sixth day injected half
of each group (chronic vehicle and chronic fenobam) with fenobam 5 minutes prior to
performing a formalin test. Regardless of whether they had been treated chronically with
fenobam or vehicle, mice acutely treated with fenobam demonstrated significantly less
spontaneous nocifensive behavior post formalin injection when compared to chronic
vehicle mice that were injected acutely with vehicle (Figure 8a). Pre-treatment with
fenobam (30 mg/kg i.p.) significantly reduced the time mice spent licking or lifting the
formalin injected paw during the first (Figure 8b) and second phase (Figure 8c)
compared to 5 day Veh / Veh mice, regardless of fenobam pretreatment.
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Spontaneous Formalin Behavior Following Figure 8: Spontaneous formalin
Chronic Fenobam Pretreatment in WT Mice behavior is reduced following five days

A

of pretreatment with fenobam

5 Day Veh / Veh
5 Day Fen / Veh
5 Day Veh / Fen
5 Day Fen / Fen

Time spent licking or
lifting injected paw (sec)

250
200

**

***

150
100
50
0

5

10

15

20

25

30

35

40

45

Time after 5% Formalin Injection

**

100

5

5

Ve
h
Fe Ve
n h
-V
5
Ve e
h h
5
Fe Fe
n n
-F
en

0

600
400
200

** **

0
Ve
h
Fe Ve
n h
5
Ve Ve
h h
5
Fe Fe
n n
-F
en

*

5

Time Spent Licking or
Lifting Injected Paw from
0 - 10 minutes (sec)

200

Phase 2
800

5

C

Phase 1
300

Time Spent Licking or
Lifting Injected Paw from
10 - 60 minutes (sec)

B

82

A) Mice that were administered fenobam
or vehicle for 5 days prior to the
formalin test demonstrated significantly
decreased time spent licking or lifting
the injected paw when administered
fenobam (30mg/kg) 5 minutes prior to
intraplantar formalin injection as
compared to mice treated with vehicle
for 5 days and vehicle on the day of the
experiment (2-Way ANOVA Main Effect
of Treatment p<0.0001; Bonferroni Post
Test **, *** = p<0.01, 0.0001 compared
to 5 Day Veh/Veh). Both the first phase
(b) and the second phase (c) were
reduced (1-Way ANOVA Main Effect of
Tr e a t m e n t p = 0 . 0 0 3 , p = 0 . 0 0 4
respectively). Dunnett’s Post Test *, **,
*** = p< 0.05, 0.01, 0.001 respectively
as compared to 5 day vehicle / vehicle
mice.

DISCUSSION
Fenobam is a potent and selective mGlu5 antagonist that has anxiolytic properties
in both rodents (Porter et al., 2005) and humans (Pecknold et al., 1980, 1982). Multiple
groups have reported that pharmacological blockade of mGlu5 is effective at reducing
nociception in several rodent pain models (Bhave et al., 2001; Karim et al., 2001; Walker
et al., 2001; Zhu et al., 2004), however these studies were the first to report the analgesic
properties of fenobam. In the present study I found that i.p. administration of fenobam
(30 mg/kg) is analgesic in three mouse models of inflammatory pain, the formalin test,
mustard oil induce nocifensive behavior, and the CFA-induced thermal hypersensitivity
test. Pretreatment with fenobam reduced the time that mice from two different strains
(Swiss Webster and C57BL/6) spent in spontaneous nocifensive behavior during the first
and second phase of the formalin test. The effects of fenobam were dose-dependent; 30
mg/kg was the lowest effective dose tested. These findings are similar to those seen when
mice are pretreated with the prototypical mGlu5 antagonist MPEP (30 mg/kg). MPEP has
been previously shown to reduce spontaneous nocifensive behaviors in the formalin test
by several groups, with minimum effective doses in mice ranging from 10 mg/kg (Varty
et al., 2005) to 30 mg/kg (Satow, et al., 2008). Comparison between fenobam and MPEP
were made at a dose of 30 mg/kg because MPEP has been shown to be effective at 30
mg/kg in reducing formalin induced nocifensive behaviors by multiple groups. These
findings suggest that fenobam is capable of reducing both the neurogenic (phase I) and
inflammatory (phase II) components of the formalin test. Fenobam was also found to be
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effective in reducing the time mice spent in nocifensive behavior following mustard oil
injection. As both mustard oil and formalin have been shown to activate the ion channel
TRPA1 (Jordt et al., 2004; McNamara et al., 2007), this suggests that mGlu5 may
modulate that particular ion channel. In addition fenobam (30mg/kg) was found to relieve
established thermal hypersensitivity induced by CFA injection. The description of
analgesic efficacy of an mGlu5 antagonist that has also been shown to be
pharmacologically active and safe in humans may provide a pharmacological tool for
assessing mGlu5 antagonists as analgesics in human clinical trials.
Initial tests were performed in outbred Swiss Webster mice. When attempts were
made to begin testing in C57BL/6 mice, a common strain used as a background for KO
animals, including the mGlu5 KO mice described here and in Chapter 2, a difference was
note in sensitivity to the drug as compared to Swiss Webster mice. Interstrain variability
in response to both opiate (Pick et al., 1991) and non-opiate analgesics (Wilson et al.,
2003) has been previously reported, and our findings suggest that different strains of mice
will also exhibit variable sensitivity to fenobam. It was hypothesized that a difference in
fenobam concentration in brain tissue or plasma might underlie the difference in
responsiveness between Swiss Webster and C57BL/6 mice, however both strains
exhibited nearly identical uptake of fenobam into brain and clearance of fenobam from
both brain tissue and plasma at all doses and time points tested. It should be noted that
mGlu5 is also expressed in the periphery (Bhave et al., 2001) and the spinal cord (Varney
and Gereau, 2002), where potential differences in fenobam concentration were not
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assessed. While the brain:plasma ratio of fenobam 5 minutes after i.p. injection was
found to vary depending on dose, this variance was noted in both strains and thus cannot
account for any observed differences. Finally, disposition studies also demonstrated that
fenobam is rapidly cleared from both brain tissue and plasma, such that when
administered at 3 or 10 mg/kg the drug is nearly absent 30 minutes after injection. This
rapid clearance may explain why the 30 mg/kg dose was required to see analgesic effect
in the formalin test.
I also sought to establish that the in vivo anti-nociceptive effects of both MPEP
and fenobam were specific for mGlu5 by testing these drugs in mGlu5 KO mice bred on
a C57BL/6 background (Lu et al., 1997). Pretreatment with fenobam (30 mg/kg i.p.) had
no demonstrated effects on mGlu5 KO mice when compared to vehicle treated animals.
Of note, the second phase of the formalin test was reduced in vehicle treated KO mice
(Figure 7F) to the same extent as in fenobam treated WT mice (Figure 7C). This effect is
consistent with the importance of mGlu5 in this phase of the formalin test such that
pharmacologic and genetic knockout of mGlu5 both reduce pain related behavior to a
similar extent (Chapter 2 Figure 5). The fact that fenobam is without effect in mGlu5 KO
mice when compared to vehicle treated littermate mGlu5 KO controls is compelling
evidence that fenobam is on target for mGlu5. MPEP (30 mg/kg), in contrast, was found
to have robust, residual analgesic effects in mGlu5 KO mice. Questions regarding the
selectivity of MPEP for mGlu5 have been noted before (Lea and Faden, 2006), and I
report here definitive evidence that the in vivo analgesic effects of MPEP in an
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inflammatory pain condition are not exclusively mediated by antagonism of mGlu5. This
finding has specific and immediate implications for the pain field, as MPEP has been the
primary antagonist used in assessing the role of mGlu5 in pain for over a decade (Lea and
Faden, 2006). Previous results obtained by a multitude of research groups, must be
considered in light of this finding. However, it is important to note that the data obtained
with MPEP in the mGlu5 KO mice should not necessarily be taken to diminish the
suggested role for mGlu5 in inflammatory pain. Indeed, as the present study indicates,
fenobam is robustly analgesic in inflammatory pain in WT but not mGlu5 KO mice,
suggesting its analgesic effects are selective for mGlu5. In addition, as reported in
Chapter 2, mglu5 KO mice have reduced hypersensitivity and nocifensive behavior in
several animal pain models. Rather than detract from a role for mGlu5 in analgesia, these
data suggest an additional mechanism for MPEP in analgesia beyond mGlu5 antagonism.
A major limitation of some analgesics, such as opiates, is that tolerance to their
analgesic effects can occur over time. Tolerance to repeated daily dosing of the mGlu5
antagonist MTEP has been demonstrated to occur in rats in the formalin test
(Sevostianova and Danysz, 2006). To determine whether tolerance to the analgesic effects
of fenobam develops, I injected mice daily for 5 days with an analgesic dose of fenobam
(30 mg/kg) or vehicle and then on the 6th day injected mice of both groups with either
fenobam or vehicle and then performed a formalin test. Mice chronically injected with
fenobam did not display tolerance to the analgesic effects of acute fenobam on the test
day. Fenobam retained its analgesic efficacy in both the first and second phase of the
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formalin test. It should be noted that this is not conclusive evidence that tolerance to
fenobam would not develop if the drug was administered over a longer time course.
However it is encouraging preliminary evidence that tolerance may not be a limiting
factor in the use of fenobam as an analgesic.
In conclusion, in this chapter I report that the clinically validated mGlu5
antagonist fenobam displays robust analgesic efficacy in three mouse models of
inflammatory pain in a manner similar to the prototypical mGlu5 antagonist MPEP. In
addition, I demonstrate that the in vivo analgesic effects of fenobam, but not MPEP, are
selective for mGlu5. These findings, along with the findings from mGlu5 KO mice
reported in chapter 2, and previous reports published in the literature, support a role for
mGlu5 antagonists as analgesics. In addition, due to previous reports that fenobam has a
good safety profile without oversedation, muscle relaxation, and interaction with ethanol,
these data suggest that fenobam may represent a reasonable candidate molecule for
testing the analgesic efficacy of pharmacologic blockade of mGlu5 in human subjects.
Prior to testing fenobam in human subjects it would be important to explore its potential
to cause undesirable side effects. While limited studies in human volunteers (BerryKravis et al., 2009), do not report any significant adverse effects of fenobam, in Chapter 4
I present expanded evidence regarding the role mGlu5 may play in locomotion, motor
coordination, and appetite by comparing the behaviors of mGlu5 KO mice compared to
WT littermates and by testing the effects of fenobam on locomotion, coordination, and
appetite in both WT and mGlu5 KO mice.
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Chapter 4
The role of mGlu5 in locomotion, motor
coordination, and appetitive behavior.
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INTRODUCTION
Evidence from both mGlu5 KO mice presented in Chapter 2 and from the mGlu5
antagonist fenobam presented in Chapter 3 suggest a clear role for mGlu5 in nociception.
Activation of mGlu5 with the agonist DHPG is pro-algesic, while genetic deletion of
mGlu5 and antagonism with fenobam result in decreased nociceptive behaviors. These
data provide encouraging evidence that mGlu5 may represent a viable therapeutic target
for the treatment of pain. However, any future development of mGlu5 antagonists as
analgesics in human patients will require drugs that are both selective for mGlu5 and
devoid of significant adverse side effects. Adverse effects may manifest as toxicity of the
parent compound or its metabolites. Unwanted effects may also result from antagonism
of mGlu5 at sites outside the pain neuraxis. The former could theoretically be solved
through medicinal chemistry and the design of new, non-toxic compounds. However
deleterious effects that are due to mGlu5 antagonism at sites outside of the pain neuraxis
would be impossible to avoid. For this reason I sought to assess both mGlu5 KO mice
and fenobam for adverse effects that could prevent the development of mGlu5
antagonists as analgesics.
Additionally, many of the measurements used to assess pain-related behavior rely
on intact motor function. Licking, lifting, flinching, and withdrawal from stimuli all
require normal motor responses. In Chapters 2 and 3 mGlu5 KO mice and WT mice
treated with fenobam were found to have decreases in hypersensitivity following CFA
injection and during the formalin test. However it is critical to verify that confounding
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alterations in motor coordination or locomotor behavior are not the reason for the
perceived reductions in pain-related behaviors. Furthermore, sedation is a common dose
limiting factor for some classes of analgesic drugs such as opiates (Melzack and Wall,
2003, p. 389). It would therefore also be warranted to test for potential undesirable
sedative effects of mGlu5 antagonists. In this chapter I describe the effects of both
fenobam and genetic deletion of mGlu5 on several sensory-motor, locomotive, and
coordination tasks. Neither pharmacological inhibition nor genetic deletion of mGlu5
was found to impair motor coordination. However, locomotive behaviors were increased
in both mGlu5 KO mice and following the administration of fenobam.
Finally, mGlu5 has been previously shown to play a role in appetite and energy
balance (Bradbury et al., 2005) and mGlu5 KO mice have also been reported to weigh
less than their WT littermates (Bradbury et al., 2005; Xu et al., 2009). I sought to confirm
the role of mGlu5 in weight gain and to determine if fenobam mediates any effects on
appetitive behavior.
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METHODS
Animals: Experiments were performed in accordance with the guidelines of the National
Institutes of Health and were approved by the Animal Care and Use Committee of
Washington University School of Medicine. Male Swiss-Webster mice (6 to 8 weeks old)
were purchased from Taconic. For experiments involving mice lacking mGlu5 (mGlu5
KO; 6 to 8 weeks old), animals were bred inhouse on a C57BL/6 background and
compared to WT littermates (Lu et al., 1997). For experiments involving KO animals the
experimenter was blinded to genotype. Blinding to genotype was accomplished by using
coded ear tag identification numbers and only breaking the code at the end of the
experiment. Genotyping of mice bred inhouse was performed using standard PCR
techniques as described in Chapter 2. All mice were group housed on a 12/12-light/dark
schedule with ad libitum access to food and water.

Chemicals and Reagents: Fenobam were purchased from Tocris (Ellisville, MO) and
dissolved in DMSO (100%) (Sigma-Aldrich, St. Louis, MO) on the day of experiment.
All intraperitoneal (i.p.) injection volumes were 20 microliters. Throughout all
experiments the investigator was blinded to pharmacological treatment.

General behavioral testing conditions: Behavioral tests were conducted in the same
general manner as described in Chapter 2.
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Sensory-Motor Battery: A series of 5 tests was performed on mGlu5 KO mice and their
WT littermates to assess gross motor behavior and coordination. All tests were performed
2 times.
Walking Initiation Test: Mice were individually placed in the center of a square outlined
in white autoclave tape (21 x 21 cm) on a smooth black surface on a large table top. The
time each mouse took to leave the square (place all four paws outside of the tape) was
recorded. The maximum time allowed was 60 seconds.

Ledge Crossing Task: Each mouse was tested to see how long it could maintain its
balance on a 0.75 cm wide plexiglass ledge without falling (60 seconds maximum). A
score of 60 seconds was also assigned if the mouse traversed the entire 51 cm length of
the ledge and returned to the starting point in less than 60 seconds without falling.

Vertical Pole Descent Task: Mice were placed head upwards at the top of a vertical metal
rod (8 mm diameter, 55 cm height). The rod was finely textured with a file to provide a
gripping surface. Mice were given a maximum of 120 seconds to turn 180 decrees and
climb down to reach the bottom of the pole and place all four paws on the tabletop. Mice
were required to reverse direction and actively climb down. If a mouse slid down the pole
without reversing direction or fell down the pole it was given a score of 120 seconds.
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Platform Sit: Mice were timed for how long they could remain on an elevated circular
platform (1 cm thick, 3 cm in diameter, 47 cm above the tabletop). A maximum score of
60 seconds was assigned to mice that remained on the platform for that amount of time.
Mice that climbed down from the elevated platform they were replaced on the platform.
If they climbed down a second time they were given a score of 60 seconds. The timer was
stopped if a mouse fell.

Screen (Angled and Inverted): Mice were placed on a wire mesh screen (16 squares per
10 cm, 47 cm high x 18 cm wide) set to three different inclinations, 60, 90, and 180
(inverted) degrees. For the 60 and 90 degree inclined tests, each mouse was placed in the
middle of the screen in a head up position and timed for how long it required to climb to
the top or bottom of the screen. A maximum time of 60 seconds was allowed. For the
inverted screen test, mice were placed on the screen oriented at 60 degrees, and then the
screen was immediately inverted to 180 degrees. The time mice spent hanging on the
screen was measured. A maximum score of 120 seconds was given to an animal that did
not fall.

Accelerating Rotarod: An accelerating rotarod (Ugo Basile, Italy) was used to assess
motor coordination. For experiments involving mGlu5 KOs, naive WT and KO
littermates were given two training sessions separated by one hour. The first training
session consisted of two trials of 120 seconds spent walking on the rotarod at a fixed
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speed of 4 RPMs. The second training session consisted of one trial of 120 seconds at 4
RPMs. All mice completed the first training session without falling in five attempts or
less; all mice completed the second training session in two attempts or less without a fall.
Latency to fall as the rotarod accelerated from 4 RPMs to 40 RPMs over 5 minutes was
assessed one hour after the second training session. Five consecutive acceleration trials
were performed with 10 minutes between each trial.
For experiments designed to assess the effects of fenobam on performance on the
accelerating rotarod, naive Swiss Webster mice received the same training paradigm as
described above. One hour after the second training session mice were injected i.p. with
fenobam (3, 10, or 30 mg/kg), pentobarbital (25 mg/kg) or vehicle (DMS). Latency to fall
as the rotarod accelerated from 4 RPMs to 40 RPMs over 5 minutes was assessed 30
minutes post injection. Again, five consecutive acceleration trials were performed with 10
minutes between each trial.

Open Field Locomotor Test: Locomotor activity was measured in an open field using a
VersaMax Animal Activity Monitoring System (AccuScan Instruments, Columbus, OH).
For experiments involving Swiss Webster mice, animals were habituated to the test room
individually in Plexiglas boxes (5 x 5 x 10 inches) for 2 hours. Thirty minutes prior to the
assessment of locomotor activity mice were injected i.p. with fenobam (3, 10, or 30 mg/
kg) or vehicle and returned to their habituation chamber. Locomotor activity was assessed
by recording photobeam breaks in a 42L x 42W x 30H cm chamber for 60 minutes. Total
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distance traveled, time spent moving, and the number of beam breaks (horizontal
activity), were calculated for the entire chamber, as well as a perimeter (outer 8 cm ring)
and center (inner 26 x 26 cm square) region. The percent of time spent in the perimeter
was also calculated as (minutes spent in perimeter / 60 minutes x 100%).
For experiments involving naive C57BL/6 WT and mGlu5 KO mice, animals
were acclimated to the testing room in their home cage for at least 2 hours. Locomotor
activity was measured individually as described above and total distance traveled was
calculated for the entire chamber.
For experiments designed to assess the effects of fenobam on locomotor behavior
in mGlu5 KO mice, animals were habituated in their home cages for at least 2 hours, and
then injected i.p. with either 30 mg/kg fenobam or vehicle (DMSO) immediately prior to
placement in the chamber. Animals were allowed to explore the chamber for 90 minutes
and locomotor activity was measured individually as described above and the total
distance traveled was calculated for the entire chamber.

Effects of Fenobam on Food Deprivation-Induced Food Intake: Food deprivation
studies were performed in a manner similar to that previously described (Bradbury et al.,
2005). For experiments designed to assess the acute effects of fenobam on food intake
mice were weighed and housed individually in their home cages three days prior to food
deprivation. The bedding was replaced with a wire mesh. On the third day mice were
weighed again and food deprived for 24 hours starting at 1 hour after lights on until 1
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hour after lights on the next day. Mice were then weighed again and injected i.p. with
either 30 mg/kg fenobam or vehicle and pre-weighed food was placed onto the cage
bottom. Food intake was measured for each mouse at 15, 30, 60, 90, and 180 minutes, as
well as at 3 hours prior to lights off (8 hours later). In order to compensate for variation of
body weight, mouse food intake was normalized to body weight. Mice were weighed to
the nearest 0.1 g and food was weighed to the nearest 0.01 g.
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RESULTS
Effects of mGlu5 Deletion on Sensory-Motor Behavior: No differences between WT
and mGlu5 KO littermates were noted when mice were required to sit on a platform for
60 seconds (Figure 1a), climb down from a pole (Figure 1b), initiate movement after
being placed in an open space (Figure 1f), or walk across a ledge (Figure 1g). No
differences were found between the time WT and mGlu5 KO mice took to reach the edge
of a 90 degree screen (Figure 1d), or hang inverted from the same screen (Figure 1e),
however there was a difference when mice were required to reach the edge of a 60 degree
screen (Figure 1c).
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Figure 1: The effects of mGlu5 Deletion on Sensory-Motor Behavior
mGlu5 and WT littermate mice had no differences in platform sit or pole climb (a-b, on previous page;
p=0.17, 0.97 respectively), (d) time to reach the edge of a 90 degree screen (p=.07), or (e) time hanging
from an inverted screen (0.33). mGlu5 KO mice took significantly longer to reach the edge or bottom of a
60 degree screen (c, 2-Way ANOVA Main Effect of Fenobam p = 0.025; No differences on Bonferroni
Post-hoc test). All unlabeled statistics are presented as 2-Way ANOVA Main Effect of Genotype. n = 7 per
group.
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Figure 1: The effects of mGlu5 Deletion on Sensory-Motor Behavior (continued)
mGlu5 and WT littermate mice exhibited no differences in (f) square exit or (g) ledge crossing (p=0.39,
0.76 2-Way ANOVA Main Effect of Genotype respectively). n = 7 per group.
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Neither mGlu5 Deletion nor Pharmacological Inhibition Affects Performance on the
Accelerating Rotarod: mGlu5 KO mice and their littermate controls showed no
differences on the accelerating rotarod (4 – 40 rpm increase over 5 min over five
consecutive trials) (Figure 2a). As compared to vehicle, fenobam injection resulted in no
significant differences in latency to fall from an accelerating rotarod at any dose tested,
up to 30 mg/kg (Figure 2b). No significant difference between vehicle-injected and
fenobam-injected Swiss Webster mice was observed over five consecutive trials. In order
to demonstrate that a reduction in fall latency could be induced, one group of mice was
injected with 25 mg/kg of pentobarbital, which resulted in a significant reduction in the
fall latency in both the first and second trials, when compared to vehicle. All groups of
Swiss Webster mice showed significant improvement in fall latency from the first to the
fifth trial.
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Figure 2: The effects of mGlu5 Deletion on Accelerating Rotarod Performance
(a) mGlu5 and WT littermate mice had no differences in performance on the accelerating rotarod (2-Way
ANOVA Main Effect of Genotype p=0.65, n=7 per group). (b) Fenobam administered 30 min prior to
placement on the accelerating rotarod did not affect latency to fall at any dose tested when compared to
vehicle. Pentobarbitol significantly decreased the latency to fall on both the 1st and 2nd trial (2-Way
ANOVA Main Effect of Drug p<0.0001, Bonferonni Post Test **, *** = p<0.05, 0.01). All groups showed
significant improvement from the 1st to 5th trial (2-Way ANOVA Main Effect of Time p<0.0001, Bonferroni
Post Test ††† = p<0.001). n = 10-12 per group.
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Both mGlu5 Deletion and Fenobam Increase Locomotor Activity in the Open Field
Task: The open field task was used to assess the effects of genetic deletion and
pharmacological inhibition of mGlu5 on locomotor activity. Swiss Webster mice were
pretreated with fenobam (3, 10, and 30 mg/kg i.p.) 30 min. prior to placement in the field
and their locomotor activity was measured. As compared to vehicle-treated animals
fenobam produced no significant effect on spontaneous exploratory behavior at 3 and 10
mg/kg, however at 30 mg/kg a significant increase in exploratory behavior was observed
in the total distance mice traveled over 60 minutes (Figure 3a,b). No significant effects
on behaviors in the center (26 cm x 26 cm) of the open field apparatus were observed
between the different doses (data not shown). No dose of fenobam was found to alter the
percent of time mice spent in the perimeter versus the center (Figure 3c,d).
When the effects of genetic deletion of mGlu5 were examined in the open field it
was found that drug naive mGlu5 KO mice traveled significantly farther in the open field
over a 60 minute time period as compared to their drug naive WT littermates (Figure
3e,f).
To assess whether the increased locomotor activity following fenobam
administration was due to inhibition of mGlu5, KO mice and WT littermates were
injected with fenobam (30 mg/kg) or vehicle (DMSO) and then immediately placed in the
open field for 90 minutes. There was a significant increase in the total distance travelled
in the fenobam treated WT mice and both the vehicle and fenobam treated mGlu5 KO as
compared to vehicle treated WT mice (Figure 3g,h).
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Figure 3: The effects of fenobam and mGlu5 Deletion on Open Field Locomotor Behavior
When administered 30 min prior to placement in a novel open field environment, Fenobam (30 mg/kg, i.p.)
significantly increased the total distance mice traveled as compared to vehicle (a) between 35 and 40 min
(2-Way ANOVA Main Effect p<0.0001; Bonferroni Post Test p<0.05) and (b) as a sum total of distance
traveled in 60 min (1-Way ANOVA p=0.0393, Dunnett’s Post Test p<0.05) (c, d) Fenobam did not decrease
the amount of time mice spent in the perimeter (outer 8cm ring) as compared to the center (inner 26 x 26
cm square) at any dose tested (2-Way ANOVA Main Effect of Fenobam p=0.11). (n = 10-11 per group.)
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Figure 3: The effects of fenobam and mGlu5 Deletion on Open Field Locomotor Behavior
(continued)
Drug-naive mGlu5 KO mice traveled significantly farther compared to their WT littermates at multiple
time points (e, 2-Way ANOVA Main Effect p<0.0001; Bonferroni Post Test *,**,*** p<0.05, 0.01, 0.001)
and as a sum total of distance traveled in 60 min (f, Unpaired t-test p=0.0044) n = 8 per group. (g-h) WT
mice traveled significantly less than all other groups at multiple time points (g, 2-Way ANOVA Main Effect
p<0.0001; Bonferroni Post Test * p<0.05) and as a sum total of distance traveled in 90 min (h, 1-Way
ANOVA p=0.0001, Bonferroni Post Test *,**,*** p<0.05, 0.01, 0.001) Fenobam did not effect the total
distance traveled in mGlu5 KO mice as compared to vehicle treated mGlu5 KOs (Bonferroni Post Test
p>0.05). n = 7-8 per group.
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mGlu5 is Required for Normal Weight Gain and Feeding Behavior: Age matched
mGlu5 KO mice weigh significantly less than their WT littermates (Figure 4a,b). The
effects of fenobam on food intake following a 24 hour food deprivation was also assessed
in WT Swiss Webster mice. Fenobam (30 mg/kg) administered at the time of refeeding
significantly decreases the amount of food consumed, as compared to vehicle treated
animals. No differences in body weight were noted in animals prior to re-feeding (Veh =
32 +/- 0.82 g, Fenobam = 31.73 +/- 1.25 g; unpaired T-test p=0.86). At 8 hours food
intake of the fenobam treated mice was not different from vehicle treated animals (Veh =
97.3 +/- 8.8 mg/g; Fenobam = 87.9 +/- 7.8 mg/g; unpaired T-test p=0.44).
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Figure 4: The effects of mGlu5 Absence and Inhibition on weight gain and post-fasting food intake.
(a) mGlu5 KO mice weigh significantly less than their WT littermates (Unpaired t-test p=0.0012). (b) No
differences in the age of animals was noted (Unpaired t-test p=0.58). n = 10 - 11 per group. (c) Fenobam
(30 mg/kg) significantly decreased food intake following a 24 hour fast as compared to vehicle (2-Way
ANOVA Main Effect of Fenobam p<0.0001, Bonferroni Post Test *, *** = p<0.05, 0.001). n = 6 per group.
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DISCUSSION
An assessment of motor coordination, locomotive behavior, and appetitive
behavior was performed in mGlu5 KO mice and WT mice treated with the mGlu5
antagonist fenobam. No differences were seen in mGlu5 KO as compared to their WT
littermates in any sensory motor behavior task with the exception of a significant
reduction in the time to reach the edge of a 60 degree screen. Interestingly mGlu5 KO
mice did not exhibit any differences from WT controls on a 90 degree screen. The
biological significance of a reduction in time to reach the edge of a 60 degree when all
other tests of sensory motor function are normal is questionable, especially when there is
no difference when that very same screen is oriented to 90 degrees inclination. Perhaps
more importantly, there were no differences in tests that are viewed as significantly more
challenging, including climbing across a narrow ledge, and down from a narrow pole.
Both of these two tasks require a mouse to navigate with limited foot purchase and
execute complex turning behaviors without falling. A test of strength where mice were
required to hang upside down for two minutes also yielded no differences.
Furthermore, no differences between mGlu5 KO and WT mice were seen on
another test of motor coordination, the accelerating rotarod. Fenobam treated mice also
exhibited no differences compared to vehicle treated controls on the accelerating rotarod.
These findings are interesting in light of findings from previous studies of MPEP and the
related mGlu5 antagonist MTEP that have reported undesirable impairment of
locomotion and motor coordination at analgesic doses (Zhu et al., 2004). While the
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results presented in Chapter 4 suggest that mGlu5 is not in fact required for normal motor
coordination, administration of fenobam at the analgesic dose (30 mg/kg) but not at lower
doses (3 and 10 mg/kg) resulted in an increase in spontaneous locomotor activity in the
open field assay.
This increase in locomotion is in contrast to the decreased locomotion reported
with MPEP (Zhu et al, 2004). Previous clinical trials of fenobam in human patients
(Friedmann et al., 1980) have reported that fenobam may have psychostimulant
properties. It is possible that the observed increases in locomotor activity reported here
are due to a similar psychostimulant effect that is separate from the locomotor inhibition
seen with MPEP. It should be noted that in figure 3a and 3b fenobam is administered 30
minutes prior to beginning open field testing and that the increases in locomotor activity
as compared to vehicle do not become readily apparent until the 40 minute time point (70
minutes post drug injection). Based on findings from our drug disposition studies
(Chapter 3), fenobam clearance is nearly complete after approximately one hour and
increased locomotion is only seen after the drug is likely cleared. Therefore, it is possible,
however speculative, that the observed increase in locomotor activity is due to the
accumulation of fenobam metabolites and not the parent compound itself. Alternatively
this could represent a “rebound” effect of unblocking mGlu5.
However, as seen in Figure 3e-h, mGlu5 KO mice exhibited increased locomotor
activity at multiple time points when compared to WT littermates. In addition when
fenobam injection occurs immediately prior to placement in the open field increased
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locomotor activity is also exhibited at multiple times points. These two findings suggest
that the increased locomotor activity is likely due to antagonism of mGlu5. Findings that
fenobam does not increase locomotor activity in mGlu5 KO mice also suggest that the
effect is mediated by mGlu5, although it is possible that ceiling effects are preventing any
increased locomotion in mGlu5 KO mice.
As mentioned, these findings of increased locomotor activity are in opposition to
those seen with MPEP (Spooren et al., 2000; Zhu et al., 2004) and the related mGlu5
antagonist MTEP (Zhu et al., 2004), which have both been shown to reduce locomotor
activity at analgesic doses. As the dose of fenobam that resulted in changes in locomotor
activity is the same as that which reduced spontaneous formalin behavior (Chapter 3), it
is possible that the analgesic effects of fenobam will prove inseparable from certain other
effects. However, motor coordination as measured on an accelerating rotarod was not
affected by fenobam at doses up to 30 mg/kg. Thus, while fenobam may increase
locomotor activity, the potentially more deleterious side effect of altered motor
coordination appears to be absent at the tested analgesic dose. Furthermore the stimulant
side effects of fenobam could actually be beneficially exploited in patients that are also
suffering from concurrent depression or malaise, assuming that any psychostimulant
effects are not aversive. No significant adverse reactions were reported when three
healthy volunteers (Berry-Kravis et al., 2009) where administered fenobam at doses of
150 mg, so it is hoped that this will be the case. Only further clinical testing in humans
will tell.
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A fascinating effect of mGlu5 deletion and pharmacological inhibition that is
likely unrelated to analgesia is a significant effect on weight gain and post-fast feeding
behavior. mGlu5 KO mice have been previously reported to weigh less than their WT
littermates (Bradbury, et al., 2005; Xu et al., 2009) and I confirm this finding here.
Differences in ad libitum food intake were not found (Bradbury, et al. 2005), so this is not
believed to account for the differences. However both mGlu5 KO mice and mice injected
with MPEP exhibit significantly less re-feeding behavior following a 14-hour fast,
suggesting that mGlu5 does play a role in appetite and feeding behavior (Bradbury et al.,
2005). Here I report that fenobam administration also significantly decreases post-fast refeeding. Fenobam’s psychostimulant properties and appetite suppressive effects should
certainly be viewed as separate from its analgesic effects. However, rather than being
dose limiting, it might be possible to exploit these effects to beneficial clinical use in
certain diseases that have pain as a major symptom. Osteoarthritis is a prime candidate as
weight loss has been associated with both a decrease in risk of developing osteoarthritis
(Felson et al, 1997) and both weight loss and increased activity result in an improvement
of existing osteoarthritis symptoms (Martin et al., 2001). Again, further testing in human
patients will be necessary to know for certain.
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Chapter 5
The Pain Related Behaviors of
Peripherally Restricted Conditional
mGlu5 KO Mice
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INTRODUCTION
The findings presented above strongly suggest that mGlu5 represents a viable
target for the treatment of pain. However, as presented in chapter 4, mice globally
deficient in mGlu5 and WT mice treated systemically with the mGlu5 antagonist
fenobam both exhibit altered behaviors unrelated to analgesia including increased
locomotor activity and altered weight gain and feeding behavior. While I make the case
that these effects may be of beneficial clinical utility in some patients, it is also possible
that they will be detrimental. As mGlu5 is expressed widely throughout the brain, it is
also possible that other centrally mediated effects of systemically active mGlu5
antagonists will also be detrimental. However, if mGlu5 expressed on peripheral
nociceptive neurons was found to play a significant role in pain transmission then it
might be possible to develop non-brain penetrant, peripherally restricted mGlu5
antagonists that would be both analgesic and devoid of centrally mediated adverse
effects.
While glutamate is the predominant excitatory neurotransmitter in the CNS it has
also been demonstrated to play a significant role as an inflammatory mediator in
peripheral tissues. Metabotropic glutamate receptor 5 is expressed on the peripheral
terminals of unmyelinated nociceptive neurons in the skin (Bhave et al., 2001). In
addition, the concentration of glutamate is increased in the skin following formalin
injection into the hind paw of the rat (Omote et al., 1998), and in the synovial fluid of
arthritis patients (McNearney et al, 2000), suggesting that peripherally released glutamate
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may be able to activate peripheral mGlu5 in pain states. As demonstrated in chapter 3,
peripheral injection of the group I mGluR agonist DHPG into the mouse hindpaw is
sufficient to generate thermal hyperalgesia that is absent in mGlu5 KO mice. Findings
that peripherally administered MPEP is analgesic in both DHPG-induced hypersensitivity
and in the formalin test (Bhave et al., 2001; Walker et al., 2001b) support the idea that
peripherally expressed mGlu5 could be targeted to analgesic effect. However, the
findings presented in chapter 3 that MPEP retains analgesic activity in mGlu5 KO mice
suggests that it may be exerting additional analgesic effect through an mGlu5independent mechanism. In this chapter I sought to address the question of whether
peripheral mGlu5 is required for the full expression of pain by employing a genetic
approach. I generated a line of conditional knockout mice lacking mGlu5 only in
primary-afferent nociceptors. I assessed the DHPG- and formalin-induced pain related
behaviors of these mice, as well as their performances on sensory-motor tasks.
These Nociceptor Specific mGlu5 (NSmGlu5) conditional knockout mice were
generated by using a Cre-LoxP technique. Mice in which the seventh coding exon was
flanked by loxP (floxed mGlu5) were crossed with a Cre-expressing transgenic mouse
line (SNS-Cre) in which Cre-Recombinase is expressed only in small diameter DRG
neurons that express Sensory Neuron Specific Sodium Channel NaV1.8. Nav1.8 is
selectively expressed in the subset of sensory neurons which are C-fiber nociceptors
(Akopian et al., 1996). The resulting offspring from these crosses will only lack mGlu5 in
peripheral sensory neurons that express NaV1.8, including virtually all unmyelinated
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neurons. (Agarwal et al., 2004). Initially there were technical hurdles involving Cremediated recombination of mGlu5 in tissues outside of the peripheral nervous system.
However, I report here that NSmGlu5 mice do not differ from floxed mGlu5 littermates
in two different pain tests, suggesting a less prominent role for peripheral mGlu5 in pain
than was previously suggested from studies using mGlu5 antagonists.
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METHODS
NSmGlu5 Breeding Scheme: Experiments were performed in accordance with the
guidelines of the National Institutes of Health and were approved by the Animal Care and
Use Committee of Washington University School of Medicine. Nociceptor specific
conditional mGlu5 KO (NSmGlu5) mice (6 to 8 weeks old) were bred inhouse on a
C57BL/6 background and compared to floxed mGlu5 littermates. NSmGlu5 mice were
generated by crossing floxed mGlu5 mice with a Cre-expressing transgenic mouse line,
in which Cre is only expressed in small diameter DRG neurons that express Sensory
Neuron Specific Sodium Channel NaV1.8 (SNS-Cre). Floxed mGlu5 mice were generated
and provided by Jian Xu and Steve Heinemann (Xu et al., 2009). We used mice in which
the Neo-cassette has been floxed out. SNS-Cre mice were generated and provided by
Nitin Agarwal and Rohini Kuner (Agarwal et al., 2004).
NSmGlu5 mice were generated by crossing the floxed mGlu5 mice with the SNSCre mice through a series of three crosses: In Cross 1: SNS-Cre mice were crossed to
floxed mGlu5 mice, generating 50% offspring that are heterozygous for both the Cre and
the floxed allele (Cre/+ \\ Flox/+). In Cross 2: Cre/+ \\ Flox/+ mice were crossed to floxed
mice generating 25% offspring that are NSmGlu5 (Cre/+ \\ Flox/Flox). In Cross 3: These
NSmGlu5 mice were mated to floxed mice, resulting in 50% floxed mice (+/+ \\ Flox/
Flox) and 50% NSmGlu5 mice (Cre/+ \\ Flox/Flox). Floxed mGlu5 and NSmGlu5 (Cross
3) were used to maintain the colony and produce progeny for experiments. NSmGlu5
mice heterozygous for the NaV1.8-Cre transgene, and homozygous for the floxed mGlu5
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allele (Cre/+ \\ FLOXmGlu5/FLOXmGlu5) were compared to control floxed mGlu5
littermates that retain full mGlu5 expression (+/+ \\ FLOXmGlu5/FLOXmGlu5).
Blinding to genotype was accomplished by using coded ear tag identification
numbers and only breaking the code at the end of the experiment. Unless otherwise
specified only male mice were tested. All mice were group housed on a 12/12-light/dark
schedule with lights on at 0600 CST and ad libitum access to food and water.

PCR Genotyping: Genotyping was performed using standard PCR techniques. Two
different genotyping protocols were used to identify the SNS-Cre transgene and the
presence of floxed mGlu5.

SNS-CRE Genotyping: One set of genotyping primers were used to verify the presence of
the SNS-Cre transgene.
Primers:
1) Forward Primer: TAT CTC ACG TAC TGA CGG TG
2) Reverse Primer: AGA CTA ATC GCC ATC TTC CAG C

Genotyping Reaction Master Mix (per reaction):
1) MilliQ Water: 19.8 µl
2) GoTaqFlexi (Promega) 5x Buffer: 5 µl
3) MgCl2 (25 mM): 1.5 µl
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4) Forward Primer: 0.5 µl
5) Reverse Primer: 0.5 µl
6) dNTPs (10 mM): 0.5 µl
7) GoTaq (Promega): 0.2 µl
8) Extracted Tail DNA - 1 µl

SNS-Cre PCR Protocol:
Cycle 1 (1x):

Step 1: 94oC for 5 min

Cycle 2 (40x):

Step 1: 94oC for 1 min
Step 2: 60oC for 1 min
Step 3: 72oC for 1 min

Cycle 3 (1x):

Step 1: 72oC for 10 min
Hold at 4oC until agarose gel separation.

Gel Separation: PCR product separation on a 1% agarose gel yields a single band of
~500 bp in mice that express the transgene. No band is detected in mice that did not
possess the transgene.
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Floxed mGlu5 Genotyping: The entire 7th coding exon of mGlu5 was flanked by LoxP as
described and two sets of primers were used for detecting the floxed allele.
Primers:
Set A:

1) Forward Primer  153  AGA TGT CCC ACT TAC CTG ATG T
2) Reverse Primer  154  AGT TCC GTG TCT TTA TTC TTA GC
3) Deletion Primer  316  AGG CGC TTC CAA AAT AGA GG

Set B:

1) Neo Primer  72  GGC TCT TTA CTA TTG CTT TAT GAT AAT G
2) Forward Primer  126  TTG CTA GCT GAA AAG GAC GAA ACA
3) Reverse Primer  127  TCG TTT TGA ATC TTG GGG ACA GTT AC

Genotyping Reaction Master Mix (per reaction):
1) MilliQ Water: Primer Set A: 9.4 µl ; Primer Set B: 7.9 µl
2) GoTaqFlexi (Promega) 5x Buffer: 4 µl
3) MgCl2 (25 mM): 2 µl
4) 1st Primer  if 154: 1 µl or if 72: 2.5 µl
5) 2nd Primer  (154 or 126): 1 µl
6) 3rd Primer  (316 or 127): 1 µl
7) dNTPs (10 mM): 0.4 µl
8) GoTaq (Promega): 0.2 µl
9) Extracted Tail DNA - 1 µl
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Floxed mGlu5 PCR Protocol (use for both primer sets):
Cycle 1 (1x):

Step 1: 94oC for 3 min

Cycle 2 (35x):

Step 1: 94oC for 30 seconds
Step 2: 52oC for 30 seconds
Step 3: 72oC for 30 seconds

Cycle 3 (1x):

Step 1: 72oC for 2 min
Hold at 4oC until agarose gel separation.

Gel Separation: PCR product separation on a 2% agarose gel yields two different sets
of three bands, depending on which primer set was used.
Primer Set A: Primer 153 hybridizes ~50 bp upstream form the first loxP site, primer
154 hybridizes ~300 bp upstream from exon 7, and primer 316 is ~240 bp
downstream of the last loxP site. PCR using primer set A yields bands of ~200 bp,
~270 bp and ~320 bp from the WT, floxed mGlu5 (with neo deletion) and del allele
respectively.
Primer Set B: Primer 126 hybridizes ~315 bp downstream of exon 7, primer 127 is
~120 bp downstream of the last loxP site, and the neo primer (72) is within the neo
cassette, ~300 bp upstream of the last loxP site. DNA from WT, floxed mGlu5 (with
neo), and floxed mGlu5 (without neo) yields 217 bp, 463 bp, and 323 bp PCR
products respectively.
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Reverse Transcription PCR rtPCR: rtPCR experiments required four steps, 1) Tissue
harvest and isolation, 2) total RNA purification, 3) Reverse Transcription of tRNA to
cDNA, 4) PCR of cDNA

Tissue Isolation: Mice were deeply anesthetized with a 100 µl injection of ketamine,
acepromizine, and xylazine (KAX) (42.86 mg/ml, 8.57 mg/ml, and 1.43 mg/ml KAX
respectively). Fresh lumbar DRGs were identified by dissecting the sciatic nerve back to
the DRG just outside the spinal cord. DRGs were then mechanically isolated using
iridectomy scissors, and transferred to RNA Later solution (Applied Biosystems/Ambion,
Austin, TX). Hippocampus was isolated from fresh brain, diced into <2 mm3 pieces with
a scalpel and transferred to RNA later solution. All tissue samples were stored at -20oC
until RNA purificiation.

Total RNA Purification: RNA was recovered from tissue using an RNeasy Micro
Purification Kit (Qiagen, Valencia, CA). Tissue was placed into 350 microliters of Buffer
RLT (Qiagen proprietary solution) with 1% β-Mercaptoethanol and mechanically
homogenized with a VWR Pellet Mixer and disposable RNASE-free plastic pestal (VWR
International, Arlington Heights, IL). Tissue was homogenized until naked-eye visible
macroscopic pieces were no longer present. The lysate was pipetted directly into a
QIAshredder spin column (Qiagen, Valencia, CA) and centrifuged at 18K x g for 2
minutes. Additional steps for RNA purification were carried out according to the Qiagen

120

RNeasy Micro Handbook (Second Edition, December 2007, pp. 27-29, steps 4 to 13). All
pipette tips were RNASE-free.

Reverse Transcription and Genomic DNA Elimination: rtPCR was performed
immediately following RNA purification using a QuantiTect Reverse Transcription Kit
(Qiagen, Valencia, CA). Four microliters of total RNA were used as template. The
protocol was carried out according to the Qiagen QuantiTect Reverse Transcription
Handbook (January 2009 Edition, pp. 12-13). cDNA was stored at -20oC until performing
PCR reactions.

PCR Genotyping: Two different primer sets were used, one directed at exon 1, which is
deleted in the global mGlu5 KO mice described in Chapter 2, and one directed at exon 7,
which is flanked by LoxP in the floxed mGlu5 mice generated by Xu et al. (2009).
Primers:
Set 1:

Forward Primer is in Exon 1, Reverse is in Exon 7
Forward Primer 1: GAG GGT TGT ACC TTC GGA TG
Reverse Primer 1: CCA GTA TCT TCG ATG GGG TG

Set 6:

Forward Primer is in Exon 6, Reverse is in Exon 8
Forward Primer 6: CTG GCC CAC TGA CGA CTT
Reverse Primer 6: CCC AGA ATG AGA AGA GCA C
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Genotyping Reaction Master Mix (per reaction):
1) MilliQ Water: 13.8 µl
2) GoTaqFlexi (Promega) 5x Buffer: 4 µl
3) MgCl2 (25 mM): 2.5 µl
4) Foward Primer: 1 µl
5) Reverse Primer: 1 µl
6) dNTPs (10 mM): 0.5 µl
7) GoTaq (Promega): 0.2 µl
8) cDNA - 1 µl

PCR Protocol (use for both primer sets):
Cycle 1 (1x):

Step 1: 94oC for 4 min

Cycle 2 (35x):

Step 1: 94oC for 45 seconds
Step 2: 55oC for 45 seconds
Step 3: 72oC for 45 seconds

Cycle 3 (1x):

Step 1: 72oC for 5 min
Hold at 4oC until agarose gel separation.

Gel Separation: PCR product separation on a 2% agarose gel yields two different sets
of bands, depending on which primer set was used.
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Primer Set 1: The forward primer hybridizes within the 0.4 kb portion of exon 1 that
has been deleted from the global mGlu5 KO mice. It is approximately 75 base pairs
from the exon 1 and 2 junction. The reverse primer hybridizes in exon 7,
approximately 20 base pairs from the exon 6 and exon 7 junction. Primer set 1 yields
an ~1160 bp product in WT mice and no product in global mGlu5 KO mice derived
from John Roder’s colony (See Chapter 2).
Primer Set 6: The forward primer hybridizes in Exon 6, approximately 5 bp from the
exon 6 and exon 7 junction. The reverse primer hybridizes in Exon 8, approximately
25 bp from the exon 7 and exon 8 junction. Primer set 6 potentially yields two bands,
one of ~1100 bp if the floxed exon (exon 7) is present, and one of ~160 bp if the 940
bp floxed exon has been excised.

Reagents and Drugs used in Behavioral Experiments: DHPG and formalin were from
the same sources and prepared in the same manner as described in Chapter 2.

General behavioral testing conditions: Behavioral tests were conducted in the same
general manner as described in Chapter 2.

Accelerating Rotarod and Open field Locomotor Test: The accelerating rotarod task
and open field locomotor tests were performed in the same manner as used to test mice
globally deficient in mGlu5 as described in Chapter 4.
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Intrathecal DHPG-Induced Spontaneous Behavior: Spontaneous i.t. DHPG-induced
behavior was assessed in the same manner as described in Chapter 2.

Spontaneous Formalin-Induced Nocifensive Behavior: Spontaneous formalin induced
nocifensive behavior was assessed in the same manner as described in Chapter 2 with one
exception. Since spontaneous nocifensive behavior was generally absent from 45 to 60
minutes in previously tested animals, behaviors were scored only for 45 minutes, instead
of 60 minutes.

Data Analysis: Statistical analysis of behavioral data was performed in the same manner
as described in Chapter 2.

124

RESULTS
Verification of Peripherally Restricted Deletion of mGlu5
PCR Genotyping: Genotyping from tail DNA was expected to produce bands at ~200 bp
and ~270 bp corresponding to WT and floxed mGlu5 genotype mice respectively.
However, a third band was also seen at ~320 bp in some mice (See Figure 1). This ~320
band corresponds to a genotype where exon 7 of mGlu5 has been excised (Xu et al,
2009). Initially genotyping was performed using a different set of primers (Xu et al,
2009), and as such this extra band was not immediately discovered. PCR of tail DNA
taken from several mice that were used as breeders in this colony were later found to
produce a band at ~320 bp. Eleven of the first 53 breeders that were set up had a band at
~320 bp. At least one mouse in 9 out 21 matings in the colony (42.9% of all matings) had
a band at ~320 bp. The presence of the CRE transgene did not affect whether the band at
~320 bp was seen. Mice B and D had the SNS-Cre transgene, while mice A and C did not
(data not shown). Some mice that were CRE-negative were found to have had a band at
~320 bp. Whether the CRE-transgene was present in the mother or the father did not
affect the appearance of a band at ~320 bp in offspring.
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WT
Figure 1: Gel of a PCR from Floxed mGlu5 Genotyping.
A representative gel showing PCR results from genotyping tail DNA from NSmGlu5 mice and their floxed
littermates. The bands on the left labelled WT and Flox are control DNA from animals previously
genotyped. Note the two bands in lane A and B corresponding to ~270 and ~320 bp respectively. Only the
~270 bp band is present in lanes C and D. Mice from A and B are interpreted as having one copy of the
floxed mGlu5 allele and one copy where the floxed section has been deleted to make a global KO allele.
Mice in lane C and D are interpreted as being homozygous floxed. Note that mice A and C did not have the
SNS-Cre Transgene, while mice B and D did. Thus, mouse A and B are actually heterozygous for mGlu5,
while mouse C is a true Flox mGlu5 mouse with no mGlu5 deletion at either locus and mouse D is an
NSmGlu5 mouse, homozygous for the floxed mGlu5 and possessing the SNS-Cre transgene.
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rtPCR: PCR amplification of cDNA from mouse DRGs and hippocampus was performed
to detect the different mGlu5 RNA species present in those tissue types. Two different
sets of primers were used to detect deletion of mGlu5. Figure 2 is a schematic of the
exons that make up the mGlu5 cDNA and the locations of the primers in that cDNA. The
four animals that are labelled A-D in Figure 1 were assessed for different cDNA species
by rtPCR (Figure 3). Animals that had a ~320 bp band in the genotyping PCR (A and B)
exhibited two bands when rtPCR was performed with primer set 6, one at ~160 bp and
one ~1100 bp. These two bands were seen in both DRGs and hippocampus (Figure 3).
Animals that did not have the band at ~320 bp (C and D) only had two bands when rtPCR
was performed in DRGs (Figure 3). When rtPCR was performed on additional mice,
including WT and global mGlu5 KO mice, two bands were only seen using primer set 6
in NSmGlu5 mice (Figure 4). Using primer set 1, all mice exhibited a band of ~1100 bp
except global mGlu5 KO mice, where no band was found in either DRGs or brain
(Figure 4). WT, floxed mGlu5, and NSmGlu5 mice only had a band at ~1100 bp using
primer set 6 (Figure 4). All mice used for behavioral experiments described below were
verified to not have a band at ~320 bp on genotyping PCR.
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6F to 6R = 1105 bp or 165 bp (if oxed out)
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Figure 2: Schematic of mGlu5 cDNA with PCR Primer Binding Sites
A graphical representation of the mGlu5 cDNA along with its UTRs. Each color change represents a
different exon. The 5’-UTR is white, the 1st exon is teal, etc. The red box represents the 95 bp addition
seen in the b splice variant of mGlu5 (Joly et al., 1995). All exons are to scale. Primer set 1 primers are
located in the 1st exon (1F) and the 7th exon (1R), 1163 bp apart. Primer set 6 primers are located in the 6th
exon (6F) and 8th exon (6F). The floxed exon is 940 bp, so primer set 6 will produce two different sized
products depending on the presence (1105 bp) or absence (165 bp) of exon 7.
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Figure 3: rtPCR of NSmGlu5 and Floxed mGlu5 mice
Representative PCR of cDNA from DRGs and hippocampus of mice with and without the ~320 bp band
detected on genotyping PCR. A and B demonstrate the 320 bp band and also show two bands, one at ~160
bp and one at ~1100 bp in both hippocampus and DRGs. C and D did not demonstrate the 320 bp band and
hippocampus from these mice only show one band at ~1100 bp. Note that mouse C also did not have the
SNS-Cre transgene and is the only mouse not to show a band at ~160 bp in the DRG. Lanes labelled “1”
are DNA generated using primer set 1 (single arrow head). Lanes labelled “6” are DNA generated using
primer set 6 (double arrow head). Other lanes are generated using primer sets not described.

129

DRG
1

WT
6

1

NS - DRG
1

6

Brain

DRG Flox

KO

DRG
1

1

6

6

6

1

6

1

6

Water

Brain
1

NS - Brain

Brain

6

1

6

Figure 4: rtPCR of WT, floxed mGlu5, NSmGlu5, and mGlu5 KO mice
Representative PCR of cDNA from DRGs and brain of all mice described in this thesis. The “NS” mouse is
a mouse that produced a band at ~320 bp when genotyping for the floxed allele was performed, suggesting
that it has an allele that is a global mGlu5 deletion. Note the two bands in the brain of this mouse. All mice,
except for the mGlu5 KO mouse exhibited a band at ~1100 bp using Primer Set 1. All mice produced a
band at ~1100 bp using primer set 6. Only the “NS” mouse produced a ~160 bp band using primer set 6.
Lanes labelled “1” are DNA generated using primer set 1 (single arrow head). Lanes labelled “6” are DNA
generated using primer set 6 (double arrow head). Other lanes are generated using primer sets not
described.
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Peripheral mGlu5 Deletion Does not Affect Open Field Locomotor Activity:
NSmGlu5 mice and their floxed littermate controls did not exhibit any difference in the
total distance travelled in the open field over a 60 minute period (Figure 5).

Open Field Exploratory Behavior
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Figure 5: The effects of Conditional mGlu5 Deletion on Open Field Locomotor Behavior
NSmglu5 mice did not differ from floxed littermates when allowed to freely explore an open field for 60
minutes (2-Way ANOVA Main Effect p=0.9106). (n = 4-6 per group.)
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Conditional mGlu5 Deletion Does Not Affect Performance on the Accelerating
Rotarod: NSmGlu5 KO mice and their littermate controls showed no differences on the
accelerating rotarod (Figure 6).
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Figure 6: The effects of Conditional mGlu5 Deletion on Accelerating Rotarod Performance
NSmglu5 mice did not differ from floxed littermates in performance on the accelerating rotarod (2-Way
ANOVA Main Effect of Genotype p=0.75, n=4-6 per group).
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DHPG-Induced Nocifensive Behaviors in NSmGlu5 Mice: Both NSmGlu5 and floxed
littermate mice exhibited nocifensive behavior following an intrathecal injection of
DHPG. There were no differences noted due to genotype (Figure 7).
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Figure 7: DHPG-Induced Spontaneous Nocifensive Behavior in NSmGlu5 Mice
NSmGlu5 mice did not differ from floxed littermates in time spent in nocifensive behavior following
intrathecal DHPG injection (2-Way ANOVA Main Effect of Genotype p=0.3961; n = 4-6 mice per group).
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Formalin-Induced Nocifensive Behavior is Not Reduced in NSmGlu5 Mice:
Nocifensive behavior, as measured by time spent licking or lifting the injected paw, was
not found to be different when NSmGlu5 mice were compared to WT littermates (Figure
8a-c).
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were compared to floxed littermates.

DISCUSSION
In chapters 2 and 3 I present data from genetic and pharmacological studies that
suggest a role for mGlu5 in the development of pain. However, data presented in Chapter
4 show that targeting mGlu5 for its analgesic potential may also induce increased
locomotor behavior and alterations in appetite and food intake, suggesting centrally
mediated effects unrelated to analgesia. In this chapter I assessed two pain related
behaviors in peripherally restricted conditional mGlu5 KO mice, in which mGlu5 is
putatively deleted only in small diameter nociceptive neurons expressing the sodium
channel NaV1.8.
NSmGlu5 mice were not found to be different from floxed control mice in two
mouse pain models, the formalin test and intrathecal DHPG-induced spontaneous
nociception. Both NSmGlu5 and floxed littermate controls exhibited a typical two phase
formalin response and were not different from each other either in the first ten minutes
(phase 1) or the last 35 (phase 2). In addition, both groups of mice exhibited spontaneous
nocifensive behavior following an intrathecal injection of DHPG. When quantified these
behaviors were not found to be different between the two groups.
Previous studies have suggested that intrathecal DHPG injection causes
spontaneous nocifensive behavior due to direct effects on spinal cord dorsal horn neurons
(Karim et al., 2001). In Chapter 2 I presented data that demonstrated a significant
reduction in nocifensive behavior following DHPG injection in global mGlu5 KO mice
compared to WT littermate controls. NSmGlu5 mice should only have mGlu5 deleted
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from peripheral nociceptors and not spinal cord neurons. Thus the finding that deleting
mGlu5 only from peripheral nociceptors does not affect DHPG-induced spontaneous
behavior, combined with data from the global mGlu5 KO mice presented in Chapter 2,
suggests that intrathecal DHPG is primarily exerting its effects on dorsal horn spinal cord
neurons or large diameter NaV1.8-negative DRG neurons. While there is some evidence
that mGlu5 expressed on the central presynaptic terminals of peripheral nociceptive
neurons may contribute to central sensitization by modulating TRPV1 (Kim et al., 2009),
the data I present above suggests that presynaptically expressed mGlu5 in NaV1.8positive neurons does not significantly contribute to spontaneous nocifensive behaviors
induced by intrathecal DHPG, at least not at the dose (50 nmols) that I have tested here.
The finding that NSmGlu5 mice do not have significantly reduced nociceptive
behaviors in the formalin test is somewhat surprising. Peripheral injection of MPEP
reduces formalin-induced spontaneous nociceptive behaviors only when injected into the
ipsilateral and not the contralateral paw (Bhave et al., 2001), suggesting a peripheral
mechanism of action. This result was taken to suggest that peripherally expressed mGlu5
might be required for the full expression of pain and it was expected that NSmGlu5 mice
would exhibit reduced responses to formalin. However, the data from the NSmGlu5 mice
presented in this chapter suggests that peripheral mGlu5 in NaV1.8-positive neurons is
not necessary for formalin induced spontaneous nocifensive behavior. It is quite possible
that peripheral mGlu5 plays a more limited role in nociception than that suggested by
previous antagonist studies. It should also be noted that the NSmGlu5 mice tested here
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should lack peripheral mGlu5 following functional Cre-Recombinase expression at P0
(Agarwal et al., 2004) and the possibility of compensation due to a lifetime of an absence
of peripheral mGlu5 could possibly account for the lack of an effect on the formalin test.
However I have no direct evidence to suggest that compensation is occurring here, and as
such the most parsimonious explanation for the formalin test findings presented above is
that peripheral mGlu5 plays a more limited role in formalin-induced nociception than was
previously thought. This may suggest a more limited role for peripheral mGlu5 in other
pain-related behaviors as well.
Compensation is but one peril of using genetically modified organisms. When
using a Cre-Recombinase / LoxP strategy to excise a gene in a tissue-specific manner any
deviation from the expected Cre-recombinase expression pattern may result in a
misinterpretation of the results. This is specifically illustrated in the findings presented
above that some NSmGlu5 mice exhibit Cre-mediated excision of the 7th exon of mGlu5
in tissues besides the DRGs. Cre transgenes can effect excision of floxed gene sequences
in the germline if the Cre-allele and floxed allele are inherited from the same parent
(Schmidt-Supprian and Rajewsky, 2007). Unfortunately, due to the desire to avoid testing
mice globally heterozygous for mGlu5, the breeding strategy that we chose to generate
the NSmGlu5 mice explicitly uses parents that express both alleles. Thus, it is likely that
the mGlu5 excision I have found in the brain may be due to cre-mediated excision of
mGlu5 in the gametes. The data presented above regarding the locomotor, rotarod, and
pain-related behaviors of NSmGlu5 mice use only mice that do not demonstrate a

137

genotyping PCR band at ~320 bp. This would suggest that they do not have a germline
excision of mGlu5, however Cre-fidelity in other tissues has not been directly assessed.
Thus, it is also possible that the lack of a difference between NSmGlu5 mice and their
floxed littermates is due to undetected ectopic Cre-expression which could result in a
mosaic expression of mGlu5. Future users of the NaV1.8 Cre mice developed by Agarwal
and Kuner will have to take care to check for cre-mediated excision of their target in
unexpected tissue. It may be advisable that future experiments designed to test the effects
of peripheral mGlu5 in nociception use a different line of mice in which Cre expression is
driven by a knock-in to the NaV1.8 locus (Stirling et al., 2005). A breeding strategy in
which mGlu5 het / Cre mice were crossed with homozygous mGlu5 floxed animals
would keep the Cre- and floxed- alleles from being inherited from the same parent.
However half of the offspring generated in this way would be globally heterozygous for
mGlu5, which could potentially confound the interpretation of behavioral experiments.
Overall the data presented in this chapter indicate that peripheral mGlu5 may not
be as encouraging a target for the treatment of pain as was previously hoped. However, to
paraphrase Bud Craig from the introduction, a mouse is not a human. Indeed there are
well known examples of the failed translation into human patients of analgesics predicted
to be efficacious by animal models (Mogil et al., 2010). The converse of that axiom is
that failed studies in mice do not necessitate failure in man. While these data presented
above would not advocate for the rational design of peripherally restricted mGlu5
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antagonists as analgesics, should serendipity provide one (for example see Porter et al.,
2005), the testing of its analgesic properties would be warranted.
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Chapter 6
Summary and Future Directions
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mGlu5 is Required for the Full Expression of Pain-Related Behaviors
Overall, the findings presented in this thesis strongly support a role for mGlu5 in
the development of pain and suggest that antagonism of mGlu5 may represent a viable
treatment option for human pain conditions. As presented in Chapter 2, intrathecal and
intraplantar injections of the group I mGluR agonist DHPG induce significantly
decreased nociceptive responses and hypersensitivity in mGlu5 KO mice, suggesting that
DHPG is exerting its pro-algesic effects by activating mGlu5. In addition, mGlu5 KO
mice have decreased spontaneous nocifensive responses induced by intraplantar injection
of formalin. Furthermore, when compared to WT littermates, these mice exhibit a faster
recovery to baseline mechanical thresholds following injection of the inflammatory agent
CFA.
In Chapter 3 I demonstrate that the mGlu5 negative allosteric modulator fenobam
reduces nocifensive behavior in WT mice. In addition, fenobam is found to be without
analgesic effect in the formalin test when administered to mGlu5 KO mice, suggesting
that fenobam’s analgesic properties are due to antagonism of mGlu5. These results
suggest that mGlu5 is required for the full expression of pain, and imply that allosteric
modulation of mGlu5 may have therapeutic effect in the treatment of pain in humans.
As discussed above, mGlu5 is expressed throughout the pain neuraxis. One of the
goals of this thesis was to determine the role that mGlu5 expressed in peripheral
nociceptive neurons plays in pain. In Chapter 5 I assessed the pain-related behaviors of
mice in which mGlu5 had been deleted exclusively from peripheral nociceptors. In
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contrast to the global mGlu5 KO mice, pain-related behaviors were not found to be
altered in peripherally restricted mGlu5 KO mice, suggesting that peripheral mGlu5
expressed in C-fiber nociceptors is not required for the development of pain. This finding
also implies that mGlu5 expressed within the central nervous system or large diameter
DRG neurons plays an important role in pain.
The finding presented in Chapter 2 that spontaneous nociceptive behaviors induced
by intrathecally injected DHPG are reduced in mGlu5 KO mice implies that activation of
mGlu5 within the spinal cord contributes to the development of pain. Additionally,
important roles for mGlu5 in pain have also been suggested within the amygdala, and
specifically within the laterocapsular division of the central nucleus (CeLC), which
receives pain projection neurons from the spino-parabrachio-amygdaloid pathway.
Multireceptive (MR) neurons within the CeLC respond to low-intensity stimuli, but are
more robustly activated by noxious stimuli. DHPG-induced activation of group I mGluRs
within the CeLC potentiates the responsiveness of amygdala MR neurons to innocuous
and noxious stimuli both in naive animals and following kaolin/carrageenan-induced
arthritis (Ji & Neugebauer, 2010; Li & Neugebauer, 2004). In addition, following arthritis
induction, MPEP both inhibits the responses of CeA neurons, and reduces the
vocalizations of awake animals following stimulation of the injured knee (Han &
Neugebauer, 2005). Administration of DHPG into the CeLC is also sufficient to induce
mechanical hypersensitivity and injection of MPEP into the CeLC is able to reverse
formalin-induced mechanical hypersensitivity (Kolber, et al., 2010). MPEP has been
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found to have residual analgesic efficacy in mGlu5 KO mice (Chapter 3), indicating that
it may be mediating this effect in an mGlu5 independent manner. However, formalininduced mechanical hypersensitivity is also significantly reduced by genetic ablation of
mGlu5 selectively within the CeLC (Kolber, et al., 2010), suggesting that CeLC
expressed mGLu5 is necessary for the development of hypersensitivity. It is therefore
possible that the analgesic effects observed following systemic injections of the mGlu5
antagonist fenobam are due to inhibition of both spinal and amygdalar mGlu5. mGlu5
activation within the spinal cord and the CeLC has been shown to activate the
intracellular signaling molecule ERK (Karim et al., 2001; Kolber et al., 2010). In turn,
ERK activation within the spinal cord and CeLC has been demonstrated to be required
for the full behavioral responses to algogenic stimuli (Karim et al., 2001; Carrasquillo &
Gereau, 2007). These findings further implicate mGlu5 as an important cellular
component of pain modulation within the spinal cord and the amygdala.
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The Translation from Pre-clinical Animal Models to Human Trials
While the findings discussed above support the targeting of mGlu5 for the
treatment of pain, additional studies also warrant caution in using mGlu5 antagonists as
analgesics due to the potential for adverse side effects. Locomotor and learning effects
were reported in mice and rats administered analgesic doses of fenobam (Chapter 4 and
Jacob et al., 2009). Additionally, findings from mGlu5 KO support a role for mGlu5 in
normal locomotor activity and in appetitive behavior and weight gain. mGlu5 KO mice
were found to have significantly higher locomotor exploratory behavior when compared
to WT mice and the mGlu5 antagonist fenobam increased locomotor behavior in WT
mice compared to vehicle injected mice. In addition, fenobam significantly suppressed
food intake following a 24 hour fasting period, suggesting that fenobam may decrease
appetite.
However, mGlu5 KO mice were found to be indistinguishable from their WT
littermates in motor coordination tasks. Also, an analgesic dose of fenobam did not affect
motor coordination assessed using an accelerating rotarod. While the alterations in
locomotor behavior and food-intake are clearly off-target, they may not sufficiently
deleterious to prevent the use of fenobam as an analgesic. Finally, no side-effects were
reported in 3 healthy human volunteers orally administered 150 mg of the fenobam
(Berry-Kravis et al., 2009), suggesting that the analgesic effects of fenobam may be ready
for assessment in human subjects.
Fenobam is not the only mGlu5 antagonist that could potentially be tested in
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humans, and several drug companies have lead compound mGlu5 antagonists in early
clinical testing. For example, Addex Pharmaceuticals has begun conducting trials of one
of its lead mGlu5 NAM compounds, ADX10059, and has reported efficacy as a treatment
for migraine in a phase 2A trial (Keywood, 2008). ADX10059 (750 mg total dose) was
reported to have a good safety profile in a separate trial examining its utility as a
treatment for gastro-esophageal reflux disease (Keywood et al., 2009). However, a phase
2B trial involving cumulative doses of ADX10059 (up to 200 mg per day) has been
recently terminated due to a higher than expected incidence of abnormal liver functions
tests (ClinicalTrials.gov ID: NCT00820105, accessed March 3, 2010). While the data
presented in this thesis suggests that mGlu5 antagonists may have utility in the treatment
of chronic pain conditions, clearly carefully conducted future testing in humans will be
necessary to ascertain whether potential analgesic effects are separable from doselimiting side effects.
In addition to treating migraine, mGlu5 antagonists may have a role in the treatment
of other pain conditions, such as post-operative pain, arthritis, and fibromyalgia. mGlu5
antagonists may be useful as mono-therapies, or in combination. For example, it is
possible that ligands acting at mGluRs may be useful as adjuvants for opiate analgesia.
NMDA receptor antagonists are known to attenuate the development of morphine
tolerance (Marek et al., 1991) and several studies have indicated that ligands for group I
and II mGluRs may have similar effects. Systemic administration of the mGlu5
antagonist MPEP and the group II mGluR agonist LY379268 have been shown to

145

improve the analgesic efficacy of morphine and reduce the development of tolerance in a
model of neuropathic pain (Kozela et al., 2003; Osikowicz et al., 2008). Further studies
will be necessary to expand upon these initial studies and to determine whether mGluR
ligands may act as adjuvants for other known analgesics, such as non-steroidal antiinflammatory agents.

146

The Heat/Capsaicin Trial as a Method for Assessing Fenobam as an Analgesic
In addition to conducting clinical trials in patients, human experimental pain
models play an important role in the assessment of the analgesic properties of novel
compounds. Predictive and non-invasive pain models can facilitate the transition from
pre-clinical testing to more expensive clinical trials by providing a cost-effective way to
assess analgesic efficacy in a limited number of healthy volunteers. Future studies should
be performed that assess the ability of fenobam to modulate human pain in healthy
volunteers, thus expanding the pre-clinical data into human subjects.
While substantial pre-clinical data exist indicating that negative allosteric
modulators of mGlu5 may mediate their analgesic effects via prevention or reversal of
central sensitization in rodents, no findings that directly test this hypothesis in human
subjects have been published. One way to address this question would be to test the
ability of fenobam to reduce the hypersensitivity caused by the heat/capsaicin
experimental hyperalgesia model in healthy human volunteers. The heat/capsaicin model
is a safe and non-invasive method that utilizes serial application of heat and capsaicin to
synergistically produce stable, long-lasting, and reproducible hyperalgesia and
hypersensitivity in human subjects (Dirks, 2003). The application of both heat and
capsaicin produces an expanded area of hypersensitivity and allodynia outside of the area
of application that is akin to that caused by central sensitization following frank tissue
injury. Multiple studies have illustrated that drugs with known analgesic efficacy,
including gabapentin (Dirks, 2002) and morphine (Frymoyer, 2007), reduce the
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hypersensitivity induced by the heat/capsaicin model. To test directly whether antagonism
of mGlu5 can reduce central sensitization in human subjects it would be possible to
induce sensitization using the heat/capsaicin model and compare the ability of fenobam to
reverse this sensitization relative to placebo in a double-blind crossover study.
Performing this study would provide direct evidence of the efficacy of fenobam to reduce
hypersensitivity in a validated human experimental model of central sensitization and
may provide the rationale for continued development of mGlu5 antagonists as analgesics
in humans.
The heat/capsaicin hyperalgesia model combines serial heat stimulation (45º C for 5
min) applied to a 15.7 cm2 area of skin on the forearm and topical low dose capsaicin
(0.1% Capzacin-HP Cream; Chattem, Chattanooga, TN) applied to the same area. This
combination produces reversible pain and the sensory changes associated with peripheral
and central sensitization for up to 4 hours. Application of thermal stimulations are applied
in a precise and controlled manner using a Medoc Advanced Thermal Stimulator (Medoc,
Ramat Yishai, Israel) driving a 9 cm2 thermode. The thermode is a computer-controlled
Peltier device that warms the skin from 32º C to a safety cutoff of 50º C in 1º C / s
increments. The heat/capsaicin model has been utilized in numerous studies involving
human subjects that demonstrate that it is safe and reliable and does not damage skin
(Abrams et al., 2007; Dirks et al., 2001, 2002, 2003).
The following methods would be used to induce and quantify pain and central
sensitization: A) pain intensity produced by 45º C thermal stimulation for 1 minute, B)

148

heat pain detection threshold to a 1º C ramp stimulus from 32º C to 50º C, C) the pain
intensity and area (in cm2) of secondary hyperalgesia and allodynia induced by the heat/
capsaicin model.
Central sensitization would be established by heating the volar surface of the
dominant forearm using the thermode set to 45º C for 5 minutes, followed by immediate
application of approximately 0.5 ounces of 0.1% capsaicin cream covering the previously
heated surface (9 cm2). The cream would be left on for 30 minutes and then wiped off. At
the end of the 30 minute capsaicin application, measurements would be performed to
determine the areas of hypersensitivity and allodynia on the forearm. The borders of
secondary hyperalgesia would be mapped using a 1 inch foam brush and a nylon Von
Frey filament (26 g bending force) along four linear paths between the thermode outline
and 1) the antecubital fossa , 2) the wrist joint, 3) the lateral aspect of the forearm in
anatomical position, and 4) the medial aspect of the forearm (Figure 1).
Hypersensitivity would be maintained by “rekindling” the site of heat/capsaicin
application by re-stimulating the previously treated skin four times at 40 minute intervals
with the thermode set to a lower temperature (40º C) for 5 min. Rekindling has been
shown to maintain robust and consistent hypersensitivity in human subjects for at least 4
hours (Dirks, 2003).
It would be possible to study the effects of fenobam on the hypersensitivity caused
by the heat/capsaicin model by calculating the change from baseline hypersensitivity due
to the effects of fenobam and comparing it to an inert placebo. Baseline would be defined
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Figure 1: The Heat/Capsaicin Model.
A) Photograph of a subject’s forearm immediately following the first rekindling. Note the erythema
within and around the thermode outline. Marked lines indicate locations where stimulation with a foam
brush was perceived as painful. Hash marks indicate locations where stimulation with a 26 g Von Frey
hair was perceived as painful. Black, red, and blue marks indicate measurements performed following
the 5 min 45º C heating, the 30 minute capsaicin application, and the first rekindling (5 min at 40º C)
respectively. B) Use of the foam brush to map out the area of hypersensitivity following capsaicin cream
application. C) Diagram demonstrating how the area of hypersensitivity from 4 hypothetical Von Frey
measurements (X marks) would be calculated.

as the size of the area of hypersensitivity immediately following the first rekindling. After
the first rekindling either fenobam (150 mg per os) or placebo would be administered.
Three post-drug rekindling sessions would then be performed. After the third post-drug
rekindling procedure the area of the hypersensitivity would be mapped and any change
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from baseline hypersensitivity would be determined. In addition, it would be possible to
quantify the fenobam plasma concentration by performing a blood draw on the volunteers
and then performing liquid chromatography-mass spectrometry on the plasma as
described in Chapter 3. Finally, assessment for tolerability and safety following fenobam
administration would be readily comparable to inert placebo.
Based on previously published findings assessing the effects of orally administered
fenobam in healthy volunteers (Berry-Kravis, 2009), it is expected that fenobam at doses
up to 150 mg will be well tolerated with minimal side effects. It is also anticipated that
fenobam administration will reduce the heat/capsaicin-induced area of hypersensitivity
on the forearm, as compared to placebo. Fenobam is also expected to reduce the pain
intensity during rekindling when compared to placebo. These findings would indicate that
fenobam is capable of reducing central sensitization and suggest a prominent role for
mGlu5 in the maintenance of central sensitization in human subjects. It would also
encourage the testing of the analgesic efficacy of fenobam in human pain patients.
In conclusion the work in this thesis supports the development of mGlu5
antagonists as analgesics, provided that care is taken in the assessment for clinically
significant deleterious effects.
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